SYNTHESIS, CLONING AND EXPRESSION OF AN ANTIFUNGAL PEPTIDE, ESF1, IN SACCHAROMYCES CEREVISIAE

by

VIVEKA VADYVALOO

Submitted in fulfilment of the academic requirements of the degree of Master of Science in the School of Molecular and Cellular Biosciences, University of Natal

Pietermaritzburg 2000
The experimental work described in this thesis for M.Sc was carried out in the School of Molecular and Cellular Biosciences, University of Natal, Pietermaritzburg, under the supervision of Professor John W. Hastings.

These studies represent the original work by the author and have not otherwise been submitted in any form for any degree or diploma to any University. Where use has been made of the work of others it is duly acknowledged in the text.

Viveka Vadyvaloo (Miss)
TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>i</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>ii</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>vii</td>
</tr>
<tr>
<td>ABBREVIATIONS</td>
<td>viii</td>
</tr>
<tr>
<td>ACKNOWLEDGMENTS</td>
<td>ix</td>
</tr>
<tr>
<td>CHAPTER ONE: LITERATURE REVIEW</td>
<td>1</td>
</tr>
<tr>
<td>1.1 An introduction to antimicrobial peptides</td>
<td>2</td>
</tr>
<tr>
<td>1.2 The nature of cationic antimicrobial peptides</td>
<td>2</td>
</tr>
<tr>
<td>1.3 Overview of antimicrobial peptides</td>
<td>3</td>
</tr>
<tr>
<td>1.3.1 Antimicrobial peptides from mammalian defense systems</td>
<td>3</td>
</tr>
<tr>
<td>1.3.2 Antimicrobial peptides from insect defense systems</td>
<td>5</td>
</tr>
<tr>
<td>1.3.3 Antimicrobial peptides from amphibians</td>
<td>9</td>
</tr>
<tr>
<td>1.3.4 Antimicrobial peptides from bees</td>
<td>11</td>
</tr>
<tr>
<td>1.3.5 Antimicrobial peptides from plant</td>
<td>13</td>
</tr>
<tr>
<td>1.3.6 Antimicrobial peptides from bacteria</td>
<td>15</td>
</tr>
<tr>
<td>1.3.7 Antimicrobial peptides from other species</td>
<td>17</td>
</tr>
<tr>
<td>1.4 Structure of cationic peptides</td>
<td>18</td>
</tr>
<tr>
<td>1.4.1 Structure-Function relationships</td>
<td>19</td>
</tr>
<tr>
<td>1.4.2 Mode of action</td>
<td>21</td>
</tr>
<tr>
<td>1.5 Applications of cationic antimicrobial peptides</td>
<td>23</td>
</tr>
<tr>
<td>1.5.1 Antimicrobial efficacy</td>
<td>23</td>
</tr>
<tr>
<td>1.5.2 Clinical applications</td>
<td>25</td>
</tr>
<tr>
<td>1.5.3 Other applications</td>
<td>25</td>
</tr>
<tr>
<td>1.5.4 Transgenic technology</td>
<td>25</td>
</tr>
<tr>
<td>1.6 Expression in yeast</td>
<td>26</td>
</tr>
</tbody>
</table>
1.6.1 Factors influencing foreign gene expression in yeast
1.6.2 Expression and secretion of heterologous proteins in yeast

1.7 The antifungal peptide, ESF1

CHAPTER TWO: MATERIALS AND METHODS
2.1 Strains, plasmids and culture conditions
2.2 DNA manipulations and transformations
   2.2.1 DNA isolations
   2.2.2 Agarose gel electrophoresis
   2.2.3 Recovery of DNA from agarose gels
   2.2.4 Enzymes
   2.2.5 Transformation
2.3 Synthetic ESF1 gene assembly
2.4 Cloning of the assembled ESF1 gene into pUC18
2.5 Cloning of the ESF1 gene into pVD4
2.6 Cloning of the ESF1/MFA1 expression cassette into pTG3828
2.7 Verification of recombinant plasmids
   2.7.1 Southern hybridization
   2.7.2 Restriction analysis
   2.7.3 Polymerase chain reaction
   2.7.4 DNA sequencing
2.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
2.9 Reverse Transcriptase PCR (RT-PCR)
2.10 Purification of ESF1 peptide from the yeast pTGESF1 transformant culture supernatant
2.11 Bioassays
2.12 Tricine SDS-PAGE
2.13 Electroblotting of protein onto polyvinylidene fluoride (PVDF) membrane
2.14 Amino acid sequencing
2.15 Electro Spray Mass Spectrometry (ES-MS) 48
2.16 Purification of antibodies produced in chickens against the synthetic ESF1 peptide 49
   2.16.1 Immunization of chickens 49
   2.16.2 Isolation of IgY antibodies from chicken egg yolks 49
   2.16.3 Purification of anti-ESF1 antibody 50
2.17 Western dot blot analysis of pTGESF1 yeast transformant culture supernatant 50

CHAPTER THREE: RESULTS AND DISCUSSION 52
3.1 Assembly of ESF1 gene sequence and its cloning into pUC18 53
3.2 Construction of the pVDESF1 recombinant vector 53
3.3 pTG3828 containing the Mfαl/ESF1 gene expression cassette isolated from E. coli transformants 57
3.4 pTG3828 containing the Mfαl/ESF1 gene expression cassette isolated from Saccharomyces cerevisiae c13ABYS86 transformants 57
3.5 Transcription of the Mfαl prepro sequence and ESF1 gene 58
3.6 Purification and detection of ESF1 peptide in PTGESF1 yeast transformant culture supernatant 59

CHAPTER FOUR: CONCLUSION 71

CHAPTER FIVE: REFERENCES 73
ABSTRACT

ESF1 is a 2.052 kDa antimicrobial peptide, mimicking the charge distribution and amphipathic alpha-helical structure of magainin, pGLa, a naturally occurring antimicrobial peptide. ESF1 has been reported to display high activity against *Fusarium oxysporum* f. sp *lycopersici* and *F. oxysporum* f. sp *cubense* race 4, the tomato and banana crop plant, wilt-causing pathogens, respectively. To assess whether this synthetic peptide can be heterologously expressed in yeast in significant quantities, and still retain full bioactivity, within a eukaryotic system, the ESF1 gene was designed and synthesized from five oligonucleotides, and cloned into pUC18. From the pUC18/ESF1 recombinant plasmid, the ESF1 gene sequence was amplified and cloned into the pBluescript-based vector, pVD4, downstream of the yeast pheromone mating factor alpha (MFα1) promoter, and in frame with the MFα1 signal peptide sequence for expression and secretion in yeast. The expression cassette comprising the MFα1 promoter and signal peptide sequence, and ESF1 gene was subsequently cloned into the yeast/E. coli shuttle vector, pTG3828 and transformed into *Saccharomyces cerevisiae*. Chicken IgY antibodies against ESF1 peptide were raised and immunoaffinity purified. Following this, western dot blot analysis and mass spectrometry confirmed the presence of ESF1 in partial HPLC purified fractions of the recombinant yeast culture supernatant.
LIST OF FIGURES

Figure 1 Examples of structures of four classes of cationic peptides. (a) β-strand human defensin-1, (b) α-helical cecropin mellitin hybrid, (c) extended coil indolicidin, (d) loop structure bactenecin. Positive charges denoted by (+), amino termini denoted by (N), and disulfide bridges are present in (a) and (d). In (a) the three β-strands are denoted by pairs of one, two or three lines on the backbone (Hancock, 1997). page 22

Figure 2 Proposed mechanism of action of cationic antimicrobial peptide with Gram negative outer membrane and the cytoplasmic membrane of bacterial cells. The hypothesized ‘self-promoted uptake’ pathway of cationic peptide into the cell, occurs when there is an association of the cationic peptide with the negatively charged outer membrane, creating cracks through which the peptide moves across the outer membrane (A); or binding to the divalent cation binding sites on LPS and disrupting the membrane (B). The peptide consequently folds into amphipathic structure (C), once bound to the negatively charged surface of the cytoplasmic membrane. Several peptide molecules insert and span the membrane after forming aggregation complexes (D), or move across the membrane under the influence of the large transmembrane potential (E). (Hancock and Chapple, 1999). page 24

Figure 3 Construction of the ESFI gene. The five oligonucleotides VV1, VV2, VV3, VV4 and VV5 were designed to compose the ESFI gene sequence. Annealing allows the joining of the complementary oligonucleotides VV1 and VV2 of the 5’ to 3’ strand to VV3, VV4 and VV5 of the 3’ to 5’ strand, while ligation facilitates joining of the VV1 to VV2, VV3 to VV4, and VV4 to VV5 oligonucleotides. page 53

Figure 4 12.5% polyacrylamide gel of putative pUC/ESFl clones restricted with BamHI/PstI to give a 78 bp fragment containing the ESFI gene. Lanes: (1) EcoRI/HindIII cleaved λ-DNA; (2) pUC/ESF1 transformant 1; (3) pUC/ESF1 transformant 2. page 54

Figure 5 pBluescript-based vector pVD4. The vector has been assembled from a basic
pBluescript vector by the introduction of the MFα1 promoter and prepro leader sequences to form an expression cassette, with the insect defensin A sequence cloned in frame with the expression cassette. This will allow expression and secretion of the cloned peptide in yeast. The underlined KpnI site contained within the insect defensin A sequence is not present in the ESF1 sequence. This allows determination of the probable replacement of insect defensin A by the ESF1 gene during restriction analysis of putative pVDESF1 clones. The arrows indicate the site of insertion for the ESF1 gene (W.F. Broekaert, personal communication).

Figure 6 Agarose gel (3%) of PCR amplification of ESF1 gene from pUCESF1 clone. Lanes: (1) 1018 bp fragment and its multimers plus pBR322 fragments; (2) pUCESF1, 1.5mM MgCl₂; (3) pUCESF1, 2mM MgCl₂; (4) pUCESF1, 2mM MgCl₂; (5) pUCESF1, 3mM MgCl₂; (6) pUCESF1, 3.5mM MgCl₂; (7) no template; (8) pMAL-p2, 1.5mM MgCl₂.

Figure 7 Agarose gel (left) and corresponding Southern blot (right) of pVD4/ESF1 (KpnI) putative hybrids. Lanes: (1) 1018 bp fragment and its multimers plus pBR322 fragments; (2) pVD4; (3) pVD4 (KpnI); (4) transformant 6b; (5) transformant 7b; and (6) transformant 8b. Digoxigenin-labeled probe VV3, which hybridizes to ESF1 was used at a hybridization temperature of 55°C.

Figure 8 Yeast/E. coli shuttle vector pTG3828. The multiple cloning site contains the SalI and BglII sites indicated by arrows at which the MFα1/ESF1 gene expression cassette can be cloned. The expression cassette will then be flanked at the 3' end by the PGK transcriptional terminator thus providing stability to the MFα1 prepro leader and ESF1 mRNA strand. The underlined ClaI site will lie 3' to the inserted expression cassette, and following cleavage of pTGESF1 DNA with SalI and ClaI, an approximate 1,3 kb fragment should be produced (Achstetter et al., 1992).

Figure 9 Agarose gel (left) and corresponding Southern blot of putative pTGESF1 recombinants. Lanes: (1) digoxigenin-labeled EcoRI/HindIII cleaved λ-DNA; (2)
pVDESF1; (3) pTG3828; (4, 5, 6, 7, 8) putative pTGESF1 clones. Digoxigenin-labeled probe, proMF, hybridizing to the MFa1 pro sequence, was used at a hybridization temperature of 42°C for Southern hybridization.

**Figure 10** Agarose gel (left) and corresponding Southern blot (right) of yeast pTGESF1 transformants. Lanes: (2) digoxigenin-labeled EcoRI/HindIII cleaved λ-DNA; (3) pTG3828 (E. coli); (4) pTGESF1 (E. coli); (5, 6, 7) pTGESF1 transformants (yeast); and (8) pTG3828 (yeast). Digoxigenin-labeled probe proMF, hybridizing to the MFa1 pro sequence was used as a probe at a hybridization temperature of 42°C in Southern hybridization

**Figure 11** Agarose gel (3%) of DNA fragments from a PCR amplification of DNA isolated from pTGESF1 transformants. Lanes: (1) 1018 bp fragment and its multimers plus pBR322 fragments; (2) transformant A5 DNA, 1.5mM MgCl₂; (3) A5 DNA, 2.5mM MgCl₂; (4) A5 DNA, 3.5mM MgCl₂; (5) A5 DNA, 4.5mM MgCl₂; (6) pTGESF1 positive control DNA, 1.5mM MgCl₂; (7) no template.

**Figure 12** RT-PCR of yeast total mRNA (A) and Southern blot (B) of the gel indicating mRNA transcription of the ESF1 gene. Lanes: (1) Digoxigenin-labeled EcoRI/HindIII cleaved λ-DNA; (2) 1018 bp fragment and its multimers plus pBR322 fragments; (3) pBR322 (HaeIII digested); (4) RT-PCR of pTGESF1 transformed yeast mRNA; (5) RT-PCR of pTG3828 transformed yeast mRNA; and (6) PCR of pVDESF1. Amplification products are noted for the reverse transcribed pTGESF1 transformed yeast mRNA and the positive control pVDESF1 DNA (contains recombinant MFa1/ESF1 expression cassette).

**Figure 13** Elution profile of synthetic ESF1 peptide using a C₁₈ Brownlee column. The retention time of the largest peak which corresponds to ESF1 activity is 31.883 minutes, and elution concentration is 41.883% acetonitrile in acidified water.
**Figure 14** Elution profile of pTGESF1 (A) and pTG3828 (B) transformed culture supernatant using Bondapak-C18 preparative HPLC column, monitored by absorbance at 220nm, using acetonitrile in acidified water as the solvent. Eluent at 30-40 minutes retention time was collected since the visible protein from the recombinant yeast culture supernatant (A) has a retention time of 33.090 minutes, which correlates with the retention time 31.883 for synthetic ESF1 peptide from a C18 analytical HPLC column.

**Figure 15** Elution profile of pTGESF1 (solid line) and pTG3828 (dotted line) transformed yeast culture supernatant using the C18 analytical HPLC column monitored at A220, using acetonitrile/acidified water as solvent. A fraction with 31-34 minutes retention time was collected, lyophilized and activity against *Carnobacterium mobile* was displayed. The peak at the retention time of 31.667 minutes is thought to represent ESF1 peptide.

**Figure 16** Spot-on-lawn assay of HPLC analytical column, lyophilized fractions of pTGESF1 and pTG3828 transformed yeast culture supernatants. 5μl of pTGESF1 (1) and pTG3828 (2) culture preparations were spotted on brain-heart-infusion agar seeded with the indicator organism, *Carnobacterium mobile*. Only the pTGESF1 culture supernatant shows activity against the indicator bacterium.

**Figure 17** Tricine (10% C; 3% T) SDS-PAGE of HPLC analytical column, lyophilized fractions of both pTGESF1 and pTG3828 transformed yeast cultures. The arrow indicates the position of the 2.052 kDa ESF1 peptide, and this band was blotted to PVDF membrane and subjected to amino acid sequencing. Lanes: (1) Promega low range protein marker, (2) Promega low range protein marker, (3) empty, (4) pTG3828 yeast culture supernatant (10μl), (5) and (6) pTGESF1 transformed yeast culture supernatant (20μl), (7) pTGESF1 transformed yeast culture supernatant (10μl).

**Figure 18** Progress of immunization with ESF1 peptide as determined by ELISA. ESF1 peptide was coated at 1μg/ml to microtitre plates and incubated with antibody dilutions of 500 μg/ml, 100 μg/ml, 50 μg/ml and 10 μg/ml, collected after 4 ( ● ), 6 ( ■ ), 8 ( ▲ ), and 9 ( ◆ ), and non-immune IgY (+). Binding was visualized by incubation with rabbit anti-
chicken HRPO-linked secondary antibody as described by Coetzer et al. (1991). Each point is a mean at A405 of duplicate samples.

**Figure 19** Representation of different immunoaffinity purified ESF1 IgY concentrations with ESF1 peptide as determined by ELISA. ESF1 peptide was coated at 1 μg/ml to microtitre plates and incubated with antibody dilutions of 100 μg/ml, 50 μg/ml, 10 μg/ml, and 1 μg/ml collected during immunoaffinity purification. Binding was visualized by incubation with rabbit anti-chicken HRPO-linked secondary antibody as described by Coetzer et al. (1991).

**Figure 20** Western dot blot of synthetic ESF1 peptide (1 μg), leucocin A peptide (1 μg), and preparative and analytical HPLC column lyophilized fractions of pTG3828 and pTGESF1 yeast culture supernatants. (1) ESF1 peptide. (2) pTGESF1 culture supernatant, preparative column fraction. (3) pTG3828 culture supernatant, preparative column fraction. (4) leucocin A peptide. (5) pTGESF1 culture supernatant, analytical column fraction. (6) pTG3828 culture supernatant, analytical column fraction. (7) empty.

**Figure 21** Electro spray mass spectrometry of synthetic ESF1 peptide and a Bondapak-C18 preparative column HPLC preparation of pTGESF1 yeast culture supernatant. The 684.27 (m/z) ration in (B, HPLC ESF1 preparation) corresponds to the 684.65 (m/z) ratio in (A, synthetic ESF1 peptide). 684 (m/z) is calculated to be 2052 Da, which reflects the ESF1 peptides mass, and this shows that ESF1 peptide is contained within preparative column fraction of the pTGESF1 culture supernatant.
LIST OF TABLES

Table 1 Bacterial peptide classes as characterized by Klaenhammer (1993). page 16

Table 2 Transgenic cationic antimicrobial peptides providing disease resistance in plants. page 28

Table 3 List of strains and plasmids used in this study. page 36

Table 4 Components of the PCR reaction mixture for amplification of the ESFI gene from the recombinant pUC/ESF1 vector. page 39

Table 5 Components of the PCR reaction mixture for amplification of the ESFI gene from the recombinant vector pTGESF1. page 44

Table 6 Components of the PCR reaction mixture for amplification of the ESFI gene from cDNA of the ESFI gene sequence from the vector pTGESF1 isolated from yeast transformant A5. page 46
## ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$A_{220}$</td>
<td>Absorbance at 220nm</td>
</tr>
<tr>
<td>ABTS</td>
<td>2,2'-azino-di-(3-ethyl)-benzothizoline sulfonic acid</td>
</tr>
<tr>
<td>AMV-RT</td>
<td>Avian myeloid virus reverse transcriptase</td>
</tr>
<tr>
<td>BCIP</td>
<td>5-bromo-4-chloro-3-indoyl-phosphate</td>
</tr>
<tr>
<td>bp</td>
<td>Base pair</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>BSA-TBS</td>
<td>Bovine serum albumin tris buffered saline</td>
</tr>
<tr>
<td>Da</td>
<td>Dalton</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme linked immunosorbent assay</td>
</tr>
<tr>
<td>ESMS</td>
<td>Electro spray mass spectrometry</td>
</tr>
<tr>
<td>f. sp.</td>
<td>formae species</td>
</tr>
<tr>
<td>HPLC</td>
<td>High pressure liquid chromatography</td>
</tr>
<tr>
<td>HRPO</td>
<td>Horse radish peroxidase</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IgY</td>
<td>Immunoglobulin Y</td>
</tr>
<tr>
<td>IPTG</td>
<td>Isopropyl-β-D-thio-galactopyranoside</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodalton</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger ribonucleic acid</td>
</tr>
<tr>
<td>NBT</td>
<td>Nitroblue tetrazolium chloride</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse transcriptase polymerase chain reaction</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris buffered saline</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
<tr>
<td>X-gal</td>
<td>5-bromo-4-chloro-3-indoyl-β-D-thio-galactopyranoside</td>
</tr>
<tr>
<td>cDNA</td>
<td>copy DNA</td>
</tr>
</tbody>
</table>
ACKNOWLEDGMENTS

I would like to express my sincere thanks and appreciation to the following people and institutions for their contribution to this thesis:

Professor John Hastings for his guidance, advice, supervision and input as supervisor during my research study, and compilation of this thesis.

Mervyn Beukes for his unending support, encouragement, advice, and brainstorming during the most trying times of my research study, and also for the invaluable friendship, willingness to help, and space in his office.

Professor Karl Kunert for his assistance and supervision at the initial stage of this project.

Drs, Theresa Coetzer, and Dean Goldring for sharing their antibody expertise with me, and also for assisting me and providing invaluable advice on production and purification of antibodies.

Ramola Chauhan, for her technical assistance with DNA and amino acid sequencing, encouragement and friendship.

Dr Thinus van der Merwe of the University of Stellenbosch, for the ES-MS analysis.

Manil Ramnath, for his support, friendship, confidence, willingness to help, for enduring my foul moods, and for his ‘tin fish’ sandwiches.

Thuli Kunene and Gina Georaras who helped preserve my sanity, and gave me days of sunshine and happy faces, encouragement and friendship.

Fellow colleagues in the ‘lab 212’, that have passed by during my research study, for the fun and laughter.
Megan Kufal for her kindness, efficiency, willingness to help, smiles and thoughtfulness.

The African Explosives and Chemical Industries (AECI) for their financial assistance.

Andrew Graham, for being the calm after the storm.

My family, for their unending love, support, understanding, inspiring belief in me and encouragement to persevere.
CHAPTER ONE
LITERATURE REVIEW
1.1 An introduction to antimicrobial peptides

Plants and animals have to survive in a world laden with pathogenic microorganisms. In order to prevent and overcome infection, plants and animals have developed many defense mechanisms. In animals, including humans, mediation of defense occurs by events such as phagocytosis, complement activation, the immune response, and the release of small, low molecular weight antimicrobial peptides. However, in lower organisms, like amphibians and insects, it is clear that small antimicrobial peptides play a major role in warding infection (Bevins and Zasloff, 1990). Thus, antimicrobial peptides have become recognized as important contributors to nonspecific host defense for both vertebrates and invertebrates. These antimicrobial peptides are easily and rapidly synthesized and have a broad specificity against prokaryotic cells and general lack of toxicity against eukaryotic hosts (Boman, 1995).

The growing incidence of antibiotic resistance amongst pathogenic microorganisms, has stimulated the search for alternative sources of antimicrobial agents that occur naturally in the environment. Antimicrobial peptides have properties that make them a potentially ideal source of new effective therapeutic agents, and this has evoked efforts to elucidate new structures, of which, more than 70 have already been identified (Boman, 1995).

1.2 The nature of cationic antimicrobial peptides

Numerous antimicrobial peptides from a variety of species have been isolated and studied. These antimicrobial peptides have been found to be typically cationic. They have a net positive charge of at least +2 at neutral pH, a minimum of four lysine and/or arginine residues, are amphipathic and usually range between 12 and 45 amino acids in length (Hancock and Lehrer, 1998; Hancock, 1997). These peptides are produced either in response to infection, or constitutively. There are two basic structural classes of cationic peptides: (1) the alpha (α)-helical peptides, especially in the presence of structure enhancing solvents, like trifluoroacetic acid, or membrane-mimicking environments;
(2) the beta (β)-sheet peptides which usually contain structure stabilizing cysteine-disulphide bonds. Some peptides contain both β-sheet elements, as well as, an associated α-helical domain, while others may contain numerous proline, tryptophan or histidine residues. However, within the great structural diversity of peptides, common structural patterns have emerged that assist in classification of these cationic antimicrobial peptides.

1.3 Overview of antimicrobial peptides

1.3.1 Antimicrobial peptides from mammalian defense systems

Mammals have a microbicidal host defense mechanism that has, as contributing factors to defense, numerous protein molecules, and these include the mammalian defense peptides that are cationic in nature. Mammalian defensins generally consist of about 29-35 amino acids, including approximately six cysteine residues that contribute to three intramolecular disulfide bonds. Mammalian defensins fall into two categories: α- or ‘classic’ defensins, and β-defensins (http://bsd.uchicago.edu/~immunobio/papers/defensin/lab.html). The α and β-defensins differ with respect to the positions and bonding pairs of their cysteine residues. They also differ with respect to their sites of expression and type of precursors they may form (Hancock and Lehrer, 1998). The cDNAs of a member from each class of defensin have been cloned. Defensins have been found to be synthesized initially as preprodefensins, the prepiece being a signal peptide for directing of the cationic peptide to the endoplasmic reticulum, and an anionic propiece, implicated in neutralizing the effect of the cationic defensin, before cleavage from the preproregion. Defensins have been isolated from granules of neutrophils of humans, rabbits, rats, guinea pigs, and hamsters (Mak et al., 1996).

As a first line of defense against invading pathogens, phagocytic neutrophils are deployed in the body. Defensin peptides are found within the neutrophil cytoplasmic granules, composing about 5-15% of the total cellular protein (Hancock et al., 1995). To date there
has been six human defense peptides isolated, designated HP 1-6. HP 1-4 are \( \alpha \)-defensins, and they exhibit varying degrees of antimicrobial and/ or virucidal properties \textit{in vitro} (Zenno et al., 1994; Inouye, 1994). HP peptides have their first and last cysteines linked and are therefore considered to be cyclic (Selsted and Harwig, 1989). In addition, they are considered to be amphipathic, since they form dimers with charged and hydrophobic molecules, clustered on two different faces of the molecule. HP-1 is able to permeabilize the outer and inner membranes of \textit{Escherichia coli}, forming voltage gated ion channels (Kagan et al., 1990).

Human beta-defensin 1 (HBD-1) has been identified in several mucosal epithelia. The constitutive expression of HBD-1 in the gingival epithelial tissue was shown by reverse transcriptase-polymerase chain reaction of HBD-1 mRNA from both inflamed and non-inflamed tissues (Krishnaprakornkit et al., 1998). It was concluded from this that HBD-1 may play a role in the maintenance of normal gingival health. Human airway epithelia also express HBD-1 which may contribute to the antimicrobial activity of airway surface fluid and mucosal defenses of the lung (McCray and Bentley, 1997). Inflamed skin has been shown to make HBD-2, whose properties have not been clearly determined as yet (Harder et al., 1997). The murine homolog of HBD-1, called mouse beta-defensin (MBD-1), has been isolated and characterized (Bals et al., 1998). MBD-1 is present in the respiratory system and the mucosal surfaces of mice.

\( \beta \)-defensin peptides that are structurally related were isolated from bovine neutrophils (Selsted et al., 1993). Tracheal antimicrobial peptide (TAP) was the first \( \beta \)-defensin 27 residue, bovine peptide to be isolated and characterized from bovine tracheal mucosa (Diamond et al., 1991). \( \beta \)-defensins are clearly distinguishable by consensus sequences at the gene and protein levels, and their disulfide array, although they are similar in size, \textit{in vitro} antibiotic activity, and structural features to other \( \beta \)-defensins (Gallagher et al., 1995). It was recently found that TAP and lingual antimicrobial peptide (LAP), also a \( \beta \)-defensin, isolated from bovine tongue, can be inducibly expressed by inflammatory mediators like bacterial lipopolysaccharide (Russell et al., 1996).
Structurally distinct from the β-defensins of bovine neutrophils, are 2 potent novel antimicrobial peptides also isolated and characterized from the larger cytoplasmic granules of bovine neutrophils. The peptide, indolicidin, is a 13-residue tridecapeptide amide, having potent antibacterial activity (Subbalakshmi et al., 1996). The primary structure of indolicidin is unique to other peptides in that it contains 5 tryptophan residues interspersed with proline residues. The other novel antimicrobial peptides from bovine neutrophils are the bactenecins, which are arginine-rich peptides (Romeo et al., 1988, Gennaro et al., 1989). Bactenecins display antibacterial activity against Gram negative and Gram positive bacteria. Two of the bactenecins can be grouped together because of their high proline content. The other bactenecin is a dodecapeptide forming a cyclic loop structure because of a disulfide bridge, formed by its 2 cysteines (Romeo et al., 1988).

Potent antibacterial cationic peptides, called protegrins, have been identified from porcine leukocytes (Kokrayakov et al., 1993). Protegrins share some similarities in sequence with mammalian defensins. Protegrin-1 is 18 amino acids in length and contains an amidated carboxyl terminus, and 2 disulfide bridges. Protegrins do however maintain a β-sheeted tertiary structure (Harwig et al., 1995). These peptides have activity against important sexually transmitted disease-causing pathogens, significantly *Neisseria gonorrhoeae* (Qu et al., 1996), *Chlamydia trachomatis* (Yasin et al., 1996), and human-immunodeficiency virus type I (Yasin et al., 1996). Protegrins are noted for their ability to maintain antimicrobial efficacy at physiological concentrations of sodium chloride (Harwig et al., 1996).

### 1.3.2 Antimicrobial peptides from insect defense systems

Insects tend to show effective resistance against infection by pathogenic microorganisms. Antimicrobial activity of the hemolymph of insects seems to be induced after the insect is challenged by microbial penetration or by injury within the humoral immune system (Hoffmann and Hoffmann, 1990). Insect defense peptides can be grouped into 4 convenient categories: (1) the cecropins which are typical amphipathic α-helical peptides approximately 4 kDa in size, and having activity against both Gram negative and Gram
positive bacteria (Hoffmann and Hetru, 1992); (2) polypeptides ranging in size from 8 kDa to 27 kDa, often rich in glycines: these include coleoptericin (Bulet et al., 1991), diptericin (Reichhart et al., 1989), sarcotoxins (Okado and Natori, 1985; Ando and Natori, 1988), 20kDa attacins (Hancock et al., 1995). The molecules are either bactericidal or bacteriostatic against Gram negative bacteria; (3) proline-rich peptides that have been isolated from Hymenoptera (Casteels et al., 1989) and Diptera (Bulet et al., 1993), and a Hemiptera bug Pyrrhocoris apterus (Cociancich et al., 1994); and (4) the insect defensins, which contain six cysteines that form 3 intramolecular disulfide bonds (Hoffmann and Hetru, 1992). Insect defensins occur throughout the insect kingdom, in insect orders including Diptera, Coleoptera, Hymenoptera, Hemiptera and Odonata. These inducible antibacterial peptides seem to be primarily active against Gram positive bacteria.

Cecropins were first isolated from the hemolymph of the giant silkworm moth, Hyalophora cecropia (Hultmark et al., 1980). The 3 principal insect cecropins are cecropin A, B and D, and they are between 35-37 amino acids long, with a structure made up of 2 amphipathic segments joined by a glycine-proline hinge (Holak et al., 1988). Gram negative bacteria are more sensitive to cecropins, than are gram positive bacteria (Boman and Hultmark, 1987). Cecropin B has been shown to disrupt the bacterial outer membrane, whereas protoplasts of human pathogenic Staphylococcus strains were resistant to cecropin B, suggesting that the cytoplasmic membrane of Gram positive bacteria are less susceptible to the peptide (Moore et al., 1996). Cecropins are thought to exert their activity by forming pores in the bacterial outer membrane, thus causing lysis of bacterial cells (Christensen et al., 1988). A 31-residue cecropin-like peptide, cecropin P1, isolated from the pig intestine, may suggest the existence of mammalian cecropins (Lee et al., 1989). Cecropin P1 offers also a variation from the α-helical basic structural class of cationic peptides, in that it has an uninterrupted 24 residue amphipathic helix which is bounded by 2-4 residues at the – and C-termini (Sipos et al., 1992).

Proline-rich peptides range from 15-34 residues in length, 25% of which are proline residues (Cherynsh et al., 1996). Proline-rich peptides usually contain arginine-proline or lysine-proline doublets, but may also contain an arginine-proline-arginine triplet which
appears in mammalian proline-rich peptides e.g. bactenecins. The first inducible antibacterial peptide, drosocin, from the fruit fly *Drosophila*, is a small, 19 residue peptide that requires an O-glycosylation in order to retain its full biological activity (Bulet et al., 1993). Besides the proline-rich peptides from the honeybee, drosocin and pyrrhocoricin both carry O-glycosylated substitution, N-acetylgalactosamine-galactose disaccharide. Metalnikowins, recently isolated and characterized from the hemipteran insect, *Palomina prasina*, are also proline-rich peptides that lack the O-glycosylation (Cherynsh et al., 1996). Metalnikowins seem to be more bacteriostatic in nature, rather than bactericidal like drosocin and pyrrhocoricin (Bulet et al., 1993; Cociancich et al., 1994).

The smaller of the glycine-rich insect defense peptides that have been isolated, are the 8 kDa diptericins, from *Phormia* and *Drosophila* species, which have 18% and 22% of glycine residues, respectively. The fat body of *Phormia* has been shown to be the site of biosynthesis of diptericins (Reichhart et al., 1989). Coleoptericin, is a 74 residue 18% glycine-rich molecule that has been isolated from the large tenebrionid beetle, *Zophobas atratus* (Bulet et al., 1991). The sarcotoxin IIA glycine-rich peptide isolated from the flesh-fly *Sarcophaga peregrina* was reported to share 30% homology at the carboxyl terminus with basic attacins, attacins being 20 kDa peptides isolated from *Cecropia* (Okado and Natori, 1988). The mode of action of sarcotoxin IIA was investigated, and it was shown that the 24 kDa peptide, affects the morphology of cells, by inhibiting cell wall synthesis, including septum formation (Ando et al., 1987). Similarly, attacins are suggested to act on the outer membrane of cells, consequently affecting the bacterial division cycle.

Insect defensins are the only group of the insect defense peptides that have disulfide bridges. These peptides have some sequence homology to rabbit lung macrophage bactericidal peptides, therefore the name ‘insect defensins’ (Lambert et al., 1989). Insect defensins differ from mammalian defensins in that they are secreted into the blood and are considered to be acute phase reactants. Insect defensins are moderately cationic (pI 8-8.5), non-glycosylated peptides, comprising 38-43 amino acids (Lepage et al., 1991). The general structure of insect defensins shows an antiparallel β-sheet linked to an amino-terminal loop by a disulfide bond, and the α-helix is stabilized to the second strand of the
β-sheet by the other 2 disulfide bonds (Hoffmann and Hetru, 1992). The variability in structure of defensins from the dipteran, coleopteran and paleopteran insect orders is the differing number of residues in the amino terminal loop (Hoffmann and Hetru, 1992). Insect defensins are also synthesized, at first, as preprodefensins. The prepiece is responsible for insertion of the peptide into the cytoplasmic reticulum, and the propiece for stabilization of the peptide (Ganz and Lehrer, 1995). Insect defensins display predominant antibacterial activity against Gram positive bacteria (Hoffmann and Hetru, 1992). The larvae of the beetle, *Allomyrina dichotoma* produces a 43 amino acid defensin that exhibits antibacterial activity against methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from a patient (Miyashonita et al., 1996). This may become significant as a potential drug for staphylococcal infection, especially with the growing number of resistant strains of medically important pathogens.

Sapecin B isolated from *Sarcophaga* is the only sapecin detected in larval brain, although it is induced similar to the sapecins in response to larval body injury. Sapecin B expression has been implicated in regulation of potassium channels in the brain, while on injury of the larval body, it is expressed in the fat body and secreted into the hemolymph to prevent bacterial infection (Lee et al., 1995).

A novel, highly basic, 42 amino acid, antibacterial peptide has been isolated from the hemolymph of the silkworm, *Bombyx mori* (Hara and Yamakawa, 1995). The peptide was named, moricin, and shows no similarity with antibacterial peptides. Moricin showed higher activity than cecropin B (also a peptide from the silkworm) to Gram positive organisms, especially *S. aureus*. The N-terminal part of the moricin molecule assumes a predicted α-helix which increases bacterial membrane permeability (Hara and Yamakawa, 1995).

Thanatin, a 21-residue peptide isolated from the insect, *Podiscus maculiventris*, exhibits the largest antimicrobial spectrum observed so far in an insect defense peptide (Fehlbaum et al., 1996). Thanatin is bactericidal and fungicidal, and has sequence homology to brevinins from frog skin (Fehlbaum et al., 1996).
1.3.3 Antimicrobial peptides from amphibians

Through approximately 30 years of research, Vittorio Erspamer and colleagues revealed that the skin of frogs has amazing significance as a source of biologically active peptides (Bevins and Zasloff, 1990). The dermatus glands of the frog synthesize and release an extensive variety of pharmacologically active peptides and antimicrobial peptides. The pharmacologically active peptides include mammalian-like hormones and neuropeptides, including angiotensin and bradykinin (Bevins and Zasloff, 1990), while the neuropeptide variety includes opioids and deltorphins (Charpentier et al., 1998). Production of cytolytic and antimicrobial cationic peptides in large amounts, is suggested to be significant in the naked skin of the frog against microbial invasion and assistance in wound recovery.

Antimicrobial peptides of the frog skin are grouped into 3 broad categories, on the basis of their sequence and structure characteristics (Nicolas and Mor, 1995): (1) Linear amphipathic helix-forming peptides, e.g magainins and related peptides from the African claw frog *Xenopus laevis*, and the dermaseptins from the South American arboreal frogs, *Phylomedusa sauvagei*. The linear amphipathic peptides show broad spectrum antimicrobial activity against yeast, protozoa, bacteria and fungi, but are not hemolytic/cytolytic. (2) Four different groups of related peptides isolated from a variety of Ranidae family species, namely brevinins-1 and -2, esculentins -1 and -2, and gaegurins. These peptides differ from linear amphipathic peptides in that they contain 2 cysteines at the carboxyl terminus that are linked in a disulfide bridge. (3) Small antimicrobial peptides of about 10-13 residues in length isolated from the *Rana temporari*, called temporins, make up the third category.

It is noted that for a particular species of amphibia, a host of unique antimicrobial peptides will be produced, having overlapping structural features, but each targeting a specific microorganism. The presence of these structurally related peptides at the same time, is thought to suggest a synergism of antimicrobial activity which lends to a more enhanced shield against a wide variety of organisms. This type of functional synergism was found to be the case when the magainins pGLa and magainin-2 were added together, in an attempt
to dissipate membrane potential against *E. coli*, permeabilize protein free liposomes for glucose, and to test for the toxic effects of tumor cells (Westerhoff *et al*., 1995).

Magainins are grouped in the first category known as, linear amphipathic helix forming peptides. The first two magainins were named magainin-1 and -2, and were isolated from the ventral skin of the frog *Xenopus laevis* (Zasloff, 1987). Magainins are also peptides that are synthesized as precursor molecules with a conserved 20 amino acid signal sequence (Zasloff, 1987; Bevins and Zasloff, 1990). The family also shares a common amino terminal processing motif, ARG-XXX-VAL-ARG, indicating a similar enzymatic cleavage activity in the processing of the mature peptide. The peptides also have an acidic amino-terminal pro region (Bevins and Zasloff, 1990; Hancock *et al*., 1995). The dermaseptin family comprise, lysine rich, amphipathic α-helical, 28-34 residue peptides, isolated from the skin secretions of *Phyllomedusa bicolor* (Charpentier *et al*., 1998), and *Phyllomedusa sauvagei* (Mor and Nicolas, 1994). While screening to assess relatedness of dermaseptin genes, a gene sequence coding for a novel dermaseptin was identified by Fleury and colleagues (1998). This novel dermaseptin was called Drg3, and exhibited 23-42% amino acid identity with the other members of the family (Fleury *et al*., 1998). The first coding exon of the *Drg3* gene contains conserved nucleotides that encompass the 25 residue preproc region of precursors of several opioids and various amphibian originating peptides (Fleury *et al*., 1998).

Besides the 3 cytolytic peptides brevinin-1, brevinin-2 and esulentin, 10 new peptides, ranging in size from 24-46 residues, all containing the carboxyl terminus intramolecular disulfide bond, were isolated from the European frog, *Rana esculenta* (Simmaco *et al*., 1994). The antimicrobial peptides of *Rana esculenta* are divided into 4 subfamilies: (1) Brevinin-1E peptides are highly hemolytic, with 6 positions occupied by the same residue in all these peptides. They are 24 residue peptides containing a proline at position 3 and a pair of basic residues at the carboxyl terminus; (2) the type 2 brevinins generally consist of 33-34 residues, except for brevinin-2Ed and -2Ee which contain a nonapeptide at the carboxyl terminus; (3) esculentins 1a, -1b and -1, are all 46 residues in length, with only 2 or 3 amino acid substitutions, respectively; (4) this group consists of the esculentins-2a and
-2b, which are 37 amino acid peptides (Simmaco et al., 1994).

1.3.4 Antimicrobial peptides from bees

Field bees are largely exposed to plant-associated microorganisms when gathering pollen and nectar. It has been found that bees produce numerous antimicrobial peptides in their hemolymph, upon challenge with foreign material. Bees belong to the insect order Hymenoptera. Similar to the other insect species discussed earlier bees also contain inducible immune systems. Bee peptides have been identified as a unique family of peptides therefore they are classed separately from other insect antimicrobial peptides. The honeybee *Apis mellifera* produces some novel antimicrobial peptides, namely, magainins (Zasloff, 1987), abaecin (Casteels et al., 1990), hymenoptaecin (Casteels et al., 1993), royalisin (Fujiwara et al., 1990), bee defensin (Casteels et al., 1993) and the apidaecins (Hancock et al., 1995).

The apidaecins isolated from the lymph fluid of the honeybee was discovered to contain 3 different isoforms, apidaecin IA, IB and II. Apidaecin consists of 18 amino acids which includes 6 proline residues and 3 arginine residues (Taguchi et al., 1994). Apidaecins are extremely stable at high temperature and low pH, and exhibit activity primarily against Gram negative and plant associated bacteria (Hancock et al., 1995) Mutational analyses of the apidaecin gene in a secretory expression system was carried out in order to determine structure-function relationship of the peptide. This study showed that the proline residues play an important role in expression of activity of apidaecin (Taguchi et al., 1994).

Besides the 3 apidaecins, a fourth bee immune response antibacterial peptide has been identified. The peptide was named abaecin, and is a 34-residue peptide with an almost 30 % proline residue composition (Casteels et al., 1990). The abaecin amino terminal is related to apidaecin and the proline motifs are similar (Casteels et al., 1990), but the abaecin differs from apidaecins in that it displays lower specific activities against Gram negative plant pathogens, and lacks the ability to inhibit bacteria at medium ionic strength.
Furthermore its highest specific activity is against an apidaecin-resistant *Xanthomonas* strain, and unlike the immediate activity that apidaecins displays, abaecin shows a delayed activity (Casteels *et al.*, 1990). This could suggest different mechanism of action for abaecin, although structurally similar to apidaecins.

Hymenoptaecin, is a 93 amino acid polypeptide isolated also from the honeybee (Casteels *et al.*, 1993). Hymenoptaecin shows no structural similarities to any of the other bee peptides isolated. It is 19 % glycine rich and contains no cysteines, although showing similarities to the insect defensin, dipterin. This large peptide inhibits viability of both Gram negative and Gram positive bacteria under physiological concentrations (Casteels *et al.*, 1993).

Royal jelly secreted from the pharyngeal glands of honeybees has extensive antimicrobial activity. Activity against both Gram negative and Gram positive bacteria, molds and fungi has been noted (Fujiwara *et al.*, 1990). Royalisin is the 51 residue peptide isolated from royal jelly. It is an amphipathic molecule and contains 3 intramolecular disulfide bridges, and sequence homology to the insect defensins, sapecin and phormicin. Royalisin is suggested to be representative of the insect defensin peptide family in bees (Hancock *et al.*, 1995).

*Apis mellifera*, also produces as the major protein component of its venom, the highly hemolytic broad spectrum antibacterial peptide, mellitin (Hancock *et al.*, 1995). Mellitin is composed of 26 amino acids and has an amide at the C-terminus (Juvvadi *et al.*, 1996). Mellitin is an amphipathic, α-helical molecule. The C-terminal segment has a basic hydrophilic, highly charged nature and is composed of 4 adjacent basic amino acids, spanning positions 21 to 24 (Juvvadi *et al.*, 1996). Mellitin is one of the best studied peptides. Two α-helical segments comprise the mellitin chain at residues 1 - 10 and 13-26, with the shape of the molecule being that of a bent rod at residues 11 and 12. Mellitin displays the property of killing eukaryotic cells. Studies on mellitin have assisted in relating the structure of peptides to their activity.
The venom of the bumblebee, *Megabombus pennsylvanicus*, has also been shown to contain 5 structurally related, hydrophobic heptadecapeptides. These 5 peptides are called bombolitins, and although not structurally related to other bee-derived peptides, they do display functional similarities to them (Argiolas and Pisano, 1985).

### 1.3.5 Antimicrobial peptides from plants

Similar to the animal kingdom, the plant kingdom has also evolved numerous different mechanisms to adapt to the constant invasion by phytopathogenic microorganisms. Over the past few years, it has become increasingly apparent that several families of small basic, cysteine rich antimicrobial peptides may also play a role in plant defense. These families include, lipid transfer proteins (Garcia-Olmedo et al., 1995), plant defensins (Terras et al., 1995), and thionins (Bohlmann and Apel, 1991).

Thionins, were the first antimicrobial peptides to be isolated from plants over 25 years ago (Fernandez de Calaya et al., 1972). Thionins have some toxic effects on bacteria (Fernandez de Calaya et al., 1972), fungi (Bohlmann and Apel, 1987), yeast (Hernandez-Lucas et al., 1974), and animal and plant cells (Reimann-Philippe et al., 1989). Thionins seems to display the conservation of 6-8 cysteine residues. The three-dimensional structure, which has been elucidated for several thionins shows an apparent homology amongst the tertiary structures. Thionin is a compact L-shaped molecule. The long arm of the L is formed by 2 α-helices, the short arm by 2 short antiparallel β-sheets, and the final (+/- 10) C-terminal residues (Bohlmann and Apel, 1991).

Thionins were first found in wheat. These wheat thionins, the first of which was named purothionin, are of low molecular weight (5 kDa), contain 45 amino acids, with 8 cysteine residues, and basic amino acids have been found throughout the molecule (Bohlmann and Apel, 1991). Other Gramineae such as barley, oats, maize and rye have also been investigated and contain similar proteins. The term 'thionin' is used to indicate the close similarity of these proteins. In dicotyledonous plants, related proteins have been found, of
which viscotoxin is the best studied. Viscotoxin was extracted from leaves and stems of mistletoe, and it contains 3 disulfide bonds, as opposed to 4 disulfide bonds in other thionins (Samuelsson, 1974). The crucifer *Crambe abyssinica* produces the thionin, crambin (Bohlmann and Apel, 1991). Crambin consists of 46 amino acids and 3 disulfide bonds is very hydrophobic, and has no positive net charge (Bohlmann and Apel, 1991). Crambin lacks notable biological activity when compared with other thionins. Leaf thionins of barley have shown potential significance in defense against pathogens. Leaf thionins isolated in the outer cell wall of the epidermal cell layer of etiolated barley leaves, show great predominance and toxicity to phytopathogenic fungi, and are therefore indicative of a resistance mechanism in barley leaves (Apel et al., 1990).

A novel class of plant peptides displaying similar structural and functional properties to insect and mammalian defensins have recently been characterized. These plant peptides were subsequently called ‘plant defensins’ (Terras et al., 1995). Plant defensins generally contain 45-54 amino acids, and have a net positive charge. It was observed also that there is limited sequence conservation in plant defensins after comparing 14 representatives spanning 13 different species of 7 different plant families. Conserved residues are confined to the 8 cysteines and 2 glycines at positions 14 and 34, a glutamic acid at position 29, and an aromatic residue at position 11 (Broekaert et al., 1995). Studies on tertiary structure of plant defensins reveals a triple-stranded, antiparallel β-sheet, and an α-helix lying parallel to the β-sheet (Broekaert et al., 1995). Plant defensins display the cysteine stabilized α-helix motif similar to insect defensins (Bruix et al., 1993).

Radish seeds have been shown to contain 2 homologous, 5 kDa cysteine rich proteins designated Rs-AFP1 and Rs-AFP2, both of which exert potent antifungal activity *in vitro* (Terras et al., 1992) and are classed as plant defensins. Studies have shown that the 2 cysteine-rich proteins are abundant in the outer layers of the cell, lining different organs of the seed; and are released after disruption of the seed coat at a concentration sufficient to provide a micro-environment around the seed which suppresses fungal growth (Terras et al., 1995).
Further studies have to be carried out to conclude sufficiently that plant defensins and thionins play a role in host defense, in the same manner as these antimicrobial peptides are defense mechanisms in animals. But to date there are several lines of evidence to support this hypothesis of these peptides being important components of the plant defense system.

1.3.6 Antimicrobial peptides from bacteria

From eukaryote to prokaryote, the production of antimicrobial peptides has been noted, although they function in entirely different environments. From the molecular perspective, many facets are similar even if there are systems required to understand antimicrobial peptides from eukaryotic systems better, and vice versa. The general term for antimicrobial peptides produced by bacteria are 'bacteriocins'. Bacteriocins have been grouped into several classes by Klaenhammer (1993) (Table 1). The fourth class of bacteriocins outlined by Klaenhammer (1993), in table 1, are characterized by their complexity and requirement of an associated lipid or carbohydrate moiety for activity (Lewus and Montville, 1992; Jimenez-Diaz et al., 1993). Contrarily, Nes and colleagues (1996) suggest that characterization of such complex bacteriocins as a class on its own may be premature, since these bacteriocins have not been adequately characterized at the biochemical level. Modified bacteriocins, similar to other antimicrobial peptides discussed previously are also produced as prepropeptides which are subsequently cleaved at the prepro leader sequence to release the biologically active peptide (Beck-Sickinger and Jung, 1991). Posttranslational modifications to lantibiotics occur in the propeptide region before cleavage of the leader sequence occurs (Sahl, 1991).

Unmodified bacteriocins require at least 4 genes and in the case of two-peptide bacteriocins, 5 genes, for its production (Nes et al., 1996). These genes are generally located in close proximity to each other. The 4 genes are the bacteriocin structural gene (2 structural genes in two-peptide bacteriocin systems), which codes for the entire prepro form of the bacteriocins; an immunity gene which encodes a protein that serves to protect the producing bacteria against the toxic bacteriocins it produces, thus providing immunity
to the producing organism; membrane associated ABC transporter gene which is involved in transfer of the bacteriocins across the cell membrane; a gene encoding an accessory protein also associated with secretion of bacteriocins (Nes et al., 1996).

The genes required for biosynthesis of lantibiotics include: (1) the structural gene encoding the prepeptide; (2) genes encoding one or more proteins required for immunity; (3) genes encoding a serine protease that is presumed to cleave of the leader peptide of the prelantibiotic; (4) genes encoding an ABC transporter likely to be involved in export of bacteriocins; (5) genes coding for one or two proteins involved in catalysis of dehydration and lanthionine ring formation; (6) the genes of two component regulatory proteins (Sahl et al., 1995) for induction of bacteriocin expression by extracellular signal transmission.

Table 1 Bacterial peptide classes as characterized by Klaenhammer (1993)

<table>
<thead>
<tr>
<th>Group I</th>
<th>Class I</th>
<th>Known as lantibiotics; 5 kDa; small membrane active peptides containing posttranslationally modified lanthionine residues</th>
</tr>
</thead>
</table>
| Modified peptide bacteriocins (Lantibiotics) | Class II | Small heat stable, non-lanthionine containing membrane-active peptides (<10 kDa) characterized by Gly-Gly-
L**+1 Xaa processing site in the bacteriocin precursor |
| Group II | Class II (a,b,c) | (a) *Listeria*-active peptides with a consensus sequence in the N-terminus of -Tyr-Gly-Asn-Gly-Val-Xaa-Cys
(b) *Poration* complexes consisting of 2 proteinaceous peptides for activity e.g., lactacin F
(c) Thiol-activated complexes requiring reduced cysteine residues for activity e.g., lactococcin B |
| Unmodified peptide bacteriocins (Non-lantibiotics) | Class III | Large heat labile-proteins, >30kDa e.g., *helveticin J* |
| | Class IV | Complex bacteriocins, composed of protein and one or more chemical moieties (lipid or carbohydrates) required for activity e.g., plantaracin S |
Comparison of lantibiotic gene clusters and encoded proteins also show non-homologous genes in some gene clusters e.g., the *nisI* gene of the nisin gene cluster, and the *spaI* gene of the subtilisin cluster, code for lipoproteins involved in immunity (Seizen *et al.*, 1996). Nisin, the first lantibiotic to be characterized is produced by *Lactococcus lactis* strains carrying a transposon-containing genes coding for the nisin precursor and biosynthesis and resistance of nisin (Kaletta and Entian, 1989). Nisin, has been used for the past 30 years and is currently widely used as a food preservative, mainly in dairy products like cheese, and in canned vegetables (Chan *et al.*, 1996).

There have not been many antimicrobial peptides isolated from fungi. Sillucin, a defensin-like peptide, active against Gram-positive bacteria, has been isolated from a thermophilic fungus, *Rhizomucor pusillus* (Hancock *et al.*, 1995).

1.3.7 Antimicrobial peptides from other species

Not many cationic peptides have been characterized in other species, besides mammals, insects, amphibians and chelicerates. Recently the crustacean shore crab, *Carcinus maenas* was reported to produce in its haemocytes, a proline-rich antibacterial peptide with sequence similarity to bactenecin-7, the antimicrobial peptide from bovine neutrophils (Schnapp *et al.*, 1996). Other crustaceans that produce antimicrobial peptides in response to bacterial infection, are the horse shoe crab species including, *Limulus polyphemus* and *Tachypleus tridentatus*. These horse shoe crabs produce 2 classes of antimicrobial peptides, the 17 residue tachyplesins and 18 residue polyphemusins, which are contained within cytoplasmic granules (Hancock *et al.*, 1995). Both classes of peptides contain cysteines which participate in 2 disulfide linkages (Matsuzaki *et al.*, 1997; Hancock *et al.*, 1995). These peptides display activity against bacteria and fungi (Hancock and Lehrer, 1998).

A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from the Moses sole fish *Pardachirus marmoratus*, have been found (Oren and Shai, 1996). Pardaxin is a 33 amino acid peptide which is structurally similar to
mellitin, comprising 2 helices with a proline hinge between them (Oren and Shai, 1996).

Blood of immune challenged and untreated mussels (*Mytilus edulis*), has been reported to produce antibacterial and antifungal peptides (Charlet *et al.*, 1996). One 34 residue peptide, mytilin, with potent antibacterial activity, and another with apparent characteristics of the insect defensins, were found in these mussels. A novel 6.2 kDa cysteine-rich antifungal peptide was also partially characterized. This may suggest that the separation of arthropods and molluscs occurred after an apparent host defense mechanism of peptides had become apparent (Charlet *et al.*, 1996).

Clavanins which are amphipathic histidine-rich, amidated α-helical peptides have been isolated from the hemocytes of the tunicate, *Styela clava* (Lee *et al.*, 1997a). These peptides are composed of 23 amino acids, and manifest potent antimicrobial activity at high salinity and acidic pH (Lee *et al.*, 1997b).

It is almost certain with the search for antimicrobial peptides in various types of species being carried out, there will definitely be a greater variety of peptides in the future to support new classifications.

1.4 Structure of cationic peptides

Basically, all the cationic peptides have 2 distinguishing features, these are: (1) a net positive charge of a minimum of +2 due to the presence of arginine and lysine residues in the peptide sequences; and modified amino acids in the case of lantibiotics; (2) the peptides are folded into a 3-dimensional structure, consisting of a hydrophobic face consisting of non-polar amino acid side chains, and a hydrophilic face of polar and positively charged residues, i.e., amphipathicity. These peptides although similar in the above-mentioned features, shows considerable variation in length, amino acid sequence, and secondary structure. Most peptides possess these general characteristics, and on secondary structure fit into 4 major classes: α-helices, extended helices with the existence of a dominant
residue throughout the peptide, β-sheet structures stabilized by 2-3 disulfide bridges, and loop structures (Hancock, 1997) (Figure 1).

Some cationic peptides, have been found to differ somewhat from the defined structural classes, sometimes incorporating more than one structural class. Sapecin, the insect defensin, contains 3 disulfide bonds, like animal defensins, but has a considerably different amino acid sequence and the presence of lysines and histidines as positively charged amino acids rather than lysines and arginines (Hanzawa et al., 1990). The solution structure of sapecin contains a flexible loop, an 8 amino acid α-helix, and 2 extended regions (Hanzawa et al., 1990). This is thought to be due to the different positions of the cysteine disulfide bonds in the animal and insect defensins. Contrary to this hypothesis, scorpion toxins with positions of disulfide bonds similar to animal defensins, have a structure comprising a short triple-stranded β-sheet region, together with a 9 amino acid α-helix (Bontems et al., 1991).

1.4.1 Structure-Function relationships

Numerous synthetic peptides have been produced in order to become more acquainted with structure-function relationships of these antimicrobial peptides. A few governing principles about structure and function on the cationic antimicrobial peptides are: (1) a change in amino acid sequence of a peptide influences the activity in a very specific manner, e.g., each position of the 26 amino acid mellitin was individually omitted to generate a series of 24 omission analogs to test for differing bioactivities amongst the analogs (Blondelle and Houghten, 1991). Testing for hemolytic activity of these analogue peptides showed that the activities were nearly the same for all the peptides, except there was increased activity in the analog lacking isoleucine at position 20 (Blondelle and Houghten, 1991). Modellins are synthetic peptides of different lengths and hydrophobicities (Bessalle et al., 1993). These amphipathic peptides were synthesized to be composed of 16-17 amino acids, a hydrophilic lysine composed face, and a highly hydrophobic face due to the tryptophan and phenylalanine residues with high antibacterial
and hemolytic activities (Bessalle et al., 1993). Replacement of tryptophan and phenylalanine with leucine, showed reduced hydrophobicity of the modellins, and a resultant decrease in hemolytic activity was noted, as well as a slightly decreased bioactivity (Bessalle et al., 1993); (2) for α-helical peptides, changes that increase the tendency to form an α-helix in aqueous solution tends to increase activity (Oh et al., 1998; Dykes et al., 1998; Blondelle and Houghten, 1991; Cornut et al., 1994); (3) it seems that no relationship exists between the number of positive charges and activity, although the position of specific positive charges is important (Powell et al., 1995; Lee et al., 1997a); (4) chirality of peptide structures have little significance (Wade et al., 1990), and full activity can be achieved with peptides containing either all L- and all D-amino acids in their respective right handed or left-handed helical conformations (Merrifield et al., 1995); (5) there is no absolute relationship between decreased lysis or binding to cells and its correlation with a decreased minimum inhibitory concentration (Hancock, 1995); and, (6) in peptides that contain cysteine disulfide bonds, a reduction of the disulfide bridges destroys activity (Hancock et al., 1995).

Synthetic peptides are now being produced in large numbers and with various modifications of structure in order to produce peptides with improved activity and decreased hemolytic activity among other required features. Length of the peptide may have some influence on cationic peptide bioactivity. There is usually decreased activity in shorter peptides (Hancock and Chapple, 1999; Bessalle et al., 1993).

Understanding the general principles that influence structure-activity relationships allows manipulation for enhanced activity. A novel cationic peptide, CP-11, which is based on the structure of the bovine neutrophil peptide, indolicidin, was designed to increase the number of positively charged residues, maintain the 13 amino acid short length, and increase amphipathicity, with respect to these features of indolicidin (Falla and Hancock, 1997). CP-11 and a carboxymethylated derivative CP-11C, demonstrated enhanced activity against Gram negative bacteria, and the yeast Candida albicans, a reduced hemolytic activity, and maintained the same activity levels as indolicidin against staphylococci (Falla and Hancock, 1997).
1.4.2 Mode of action

There have been numerous studies to determine the mode of action of the cationic antimicrobial peptides, specifically the cecropins, magainins, mellitins and defensins (Hancock and Lehrer, 1998). Currently, the main site of action of these peptides is the cytoplasmic membrane (Falla et al., 1996; Hancock, 1995; Matsuzaki et al., 1997). In Gram positive bacteria the interaction is only with one membrane, i.e., the cytoplasmic membrane. On the other hand, Gram negative bacterial species require, a more involved interaction due to the existence of an outer membrane, and a cytoplasmic membrane.

The predicted mechanism of action based on the model of Christensen et al (1988) (Figure 2), states that there is an initial electrostatic interaction between the negatively-charged phospholipid bilayer of the cytoplasmic membrane and the cationic peptide. The bacterial cytoplasmic membrane has a large electric potential, and this influences transition of peptides from an unstructured to structured form. There is an aggregation of peptides in a manner that results in the hydrophobic faces of the peptides being directed toward the interior of the membrane and their hydrophilic faces form the channel pointing inwards. Insertion of these aggregated peptides into the cytoplasmic membrane results in destruction of membrane integrity, and subsequent bacterial cell death, caused by the leakage of cytoplasmic molecules. Factors that favour the formation of channels include, high negatively charged lipid composition of the phospholipid bilayer, large transmembrane potentials maintained by the proton motive force, a lack of cationic lipids and cholesterol (Christensen et al., 1988), which is characteristic of bacterial membranes (Hancock, 1997).

Eukaryotic membranes have cholesterol as part of the lipid composition of the cell’s membrane, low membrane potentials and low anionic lipid content, and this could be an explanation for the cationic peptide’s specificity for bacterial cell membranes (Boman, 1995). An alternative to the more accepted hypothesis is that the cationic antimicrobial peptides cluster at the cytoplasmic membrane surface and cause a cooperative permeabilisation of the cytoplasmic membrane, also referred to as the ‘carpet effect’ (Boman, 1995).
For Gram negative bacterial species it has been proposed that cationic antimicrobial peptides interact with the bacterial outer membrane lipopolysaccharide (LPS), and are taken up by a ‘self-promoted uptake’ pathway (Hancock, 1997; Hancock et al., 1995; Hancock and Lehrer, 1998). The LPS of the outer membrane of Gram negative bacteria is a highly anionic glycolipid. Initiation of the ‘self-promoted uptake’ pathway occurs when the cationic antimicrobial peptide, interacts with the anionic, divalent cation-binding sites on LPS. It has been reported that the addition of 2 positive charges on the carboxyl terminus of a cecropin-mellitin hybrid (CEME), resulted in an enhanced interaction of the peptide with LPS and consequently, the outer membrane (Piers and Hancock, 1994). Direct interactions of other cationic peptides like magainins and defensins with LPS have been demonstrated (Hancock et al., 1995). These interactions seem to be several orders of magnitude higher than the normal divalent cations, demonstrating that this binding is quite
an efficient process. This interaction causes disruption to the normal outer membrane barrier properties by the production of transient 'cracks', which permits the passage of various small molecules, like the cationic antimicrobial peptides, into the cell (Hancock, 1997; Piers and Hancock, 1994) (Figure 2). It is assumed that peptides, that are specific for Gram positive bacteria, lack the ability to access the 'self-promoted uptake' pathway because of the absence of the outer membrane.

Mode of action studies done on lantibiotics show that unlike the amphipathic pore-forming lantibiotics e.g., nisin (Sahl, 1991), the globular lantibiotics appear to be involved in inhibition of enzyme reactions (Brötz et al., 1997). Studies done on the lantibiotic mersacidin, in particular, indicates no impairment of the overall integrity of the cell membrane (Brötz et al., 1998), but instead it exerts bactericidal action by the inhibition of the transglycosylation level of peptidoglycan biosynthesis by the interaction of the Lipid II component of peptidoglycan (Brötz et al., 1998). The lantibiotic actagardine also shows similarity to mersacidin with respect to its mechanism of bactericidal activity (Brötz et al., 1998). Mersacidin and actagardine are of similar size and hydrophobicity, contain 4 intramolecular thioether bridges, and consequently the same globular structure (Brötz et al., 1997). The findings are significant in that there may be different mechanisms of action of different peptides depending on their structures, and that not all antimicrobial peptides have the same mode of action.

1.5 Applications of cationic antimicrobial peptides

1.5.1 Antimicrobial efficacy

Naturally occurring cationic antimicrobial peptides have a wide range of bioactivity levels
that include a defined to broad spectrum of susceptible microorganisms, and from very potent to weak bioactivity (Hancock and Chapple, 1999). The design of synthetic peptides can be such that these peptide products are non-toxic and can achieve effectively low minimal inhibitory concentrations (MICs) against a broad spectrum of microorganisms. Peptides have the advantage of: (1) being antimicrobial at the MIC, and causing rapid killing within 5 minutes at about 4 times the MIC; (2) being unaffected by common clinical resistant mechanisms like methicillin resistant *S. aureus*, thus affording difficult
selection of peptide resistant pathogens; and, (3) showing ability to protect both local and systemic infection in animal models (Hancock and Chapple, 1999; Hancock, 1997).

### 1.5.2 Clinical applications

The pharmaceutical company AMBI, produced ambicin (company name for nisin) and have managed to pass the peptide through phase I clinical trials successfully. Ambicin is being considered as a potential treatment of ulcers caused by *Helicobacter pylori*; and as a replacement treatment for vancomycin to kill of the antibiotic-associated diarrhoeal bacterium *Clostridium difficile*, and vancomycin-resistant enterococci that cause increased risk of patients to lethal systemic infection (http://www.businesswire.com/webbox/bwII1897/536701.htm; Hancock and Chapple, 1999). MSI-78 (Magainin pharmaceuticals), which is also an α-helical magainin variant peptide, has been passed phase III clinical trials for the treatment of diabetic foot ulcers (Hancock and Lehrer, 1998; http://www.pslgroup.com/dg/2168e.htm).

### 1.5.3 Other applications

Nisin was introduced by the company Aplin and Barett as nisaplin, in 1957, and is currently being used as a food preservative by over 50 countries. Nisin formulated with 1-propanol has proved to be highly bactericidal against Gram negative pathogens and is now produced as a teat dip to prevent mastitis in cattle (Hancock and Lehrer, 1998). These cationic antimicrobial peptides have also been used in the preservation of cut roses (Florack et al., 1996).

### 1.5.4 Transgenic technology

It would be feasible to improve the resistance of various species to microbial infection by
attempting to overproduce cationic antimicrobial peptides and synthetic variants thereof by using transgenic technology. This transgenic approach has been attempted several times in plants but with mixed results (Table 2). Transgenic tobacco plants producing the Shiva-1 peptide, a synthetic cecropin B analog, displayed resistance to the bacterial wilt pathogen, *Pseudomonas solanacearum* (Jaynes et al., 1993). SB37 another cecropin B analog showed no increased resistance to bacterial diseases (Cavallarin et al., 1998). The difficulty that seems to be inherent with antimicrobial peptides being introduced into plants to improve their resistance to pathogens, is the peptides susceptibility to intracellular proteases (Cavallarin et al., 1998). Protection of antimicrobial peptides against degradative enzymes within plants would probably require further modeling of the peptide to produce substitution analogs lacking the protease activity site.

Recombinant techniques that have been explored to reduce cost and for easy production methods include, production in insect cells using baculovirus expression systems, yeast expression vectors (Romanos et al., 1992), and in the milk of transgenic mice (Hancock and Lehrer, 1998). However, the exact commercial potential of these procedures has yet to be determined.

Another novel example of transgenic technology has been the introduction of a cecropin A peptide into the endosymbiont bacterium, *Rhodnius prolixus*. This leads to the elimination of *Trypanosoma cruzi* parasite after transformation of the transgenic *R. prolixus* into the disease-transmitting insect (Durvasula et al., 1997).

### 1.6 Expression in yeast

Yeasts are unicellular eukaryotic organisms. These organisms have become attractive systems in the various facets in modern biotechnology. Generally they make effective host organisms for the production of heterologous proteins, specifically eukaryotic proteins. Yeast expression systems on the whole are advantageous in that they possess the ease of genetic manipulation and growth characteristics of prokaryotic organisms, in combination
with the subcellular machinery for complex post-translational modifications (Romanos et al., 1992; Cregg et al., 1993; Gellisen and Hollenberg, 1997). A wide range of yeast species, including *Saccharomyces cerevisiae*, *Pichia pastoris*, *Hansenula polymorpha*, *Kluyveromyces lactis*, *Schizosaccharomyces pombe* and *Yarrowia lipolytica*, have been used for foreign gene expression. Foreign gene expression in yeast has become an important tool for the production of foreign proteins for research, industrial or medical use (Romanos et al., 1992).

### 1.6.1 Factors influencing foreign gene expression in yeast

Yeasts being eukaryotic organisms possess similar characteristics to higher eukaryotes and mammalian cells regarding their physiology, protein secretion and basic genetics. Yeasts require simple and accessible nutrition which permits them to be cultured rapidly to a very high cell density (Kukuruzinska et al., 1987). The complete nucleotide sequencing of the yeast genome in 1996 (Goffeau et al., 1996), has facilitated further research that has provided information on various aspects of yeasts including, their growth and cell cycle. The increasing research and information produced on yeast has made it more accessible to easy manipulation. Yeasts possess a highly compartmentalized intracellular organization and with this an elaborate secretory pathway which mediates the secretion and modification of many host proteins. This ability for extracellular secretion of heterologous proteins into culture medium allows the avoidance of toxic accumulated material. Extracellular secretion also affords simple purification procedures for the protein being expressed because not only does the yeast organism secrete very low levels of endogenous proteins (Eckart and Bussineau, 1996), but the yeast expression systems have been genetically manipulated to provide protease-negative mutant host strains for cloning.
### Table 2 Transgenic cationic antimicrobial peptides providing disease resistance in plants

<table>
<thead>
<tr>
<th>Peptide used</th>
<th>Species transformed</th>
<th>Expression levels</th>
<th>Pathogen resisted</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>cecropin B</td>
<td>tobacco</td>
<td>not determined</td>
<td><em>Pseudomonas campestris pv. tabaci</em></td>
<td>Huang et al., 1997</td>
</tr>
<tr>
<td>tachyplesin I</td>
<td>potato</td>
<td>low expression level</td>
<td>low <em>Erwinia</em> resistance</td>
<td>Allefs et al., 1996</td>
</tr>
<tr>
<td>plant defensin Rs-AFP2</td>
<td>tobacco</td>
<td>0.2-24 µg/mg leaf protein</td>
<td><em>Alternaria longipes</em></td>
<td>Epple et al., 1997</td>
</tr>
<tr>
<td>Amaranth hevein Ac-AMP2</td>
<td>tobacco</td>
<td>0.6-1.1 µg/mg leaf protein</td>
<td>Shows in vitro antifungal resistance only</td>
<td>De Bolle et al., 1996</td>
</tr>
<tr>
<td>Sweet Pepper Knott in</td>
<td>tobacco</td>
<td>0.9-1.4 µg/mg leaf protein</td>
<td>Shows in vitro antifungal resistance only</td>
<td>Jaynes et al., 1993</td>
</tr>
<tr>
<td>Mj-AMP2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shiva-1 and SB37</td>
<td>tobacco</td>
<td>up to 1 µg/mg leaf protein</td>
<td>bacterial wilt pathogen</td>
<td>Jaynes et al., 1993</td>
</tr>
<tr>
<td>cecropin B analogs</td>
<td></td>
<td></td>
<td><em>Pseudomonas solanacearum</em></td>
<td></td>
</tr>
<tr>
<td>SB37</td>
<td>potato</td>
<td>up to 1 µg/mg</td>
<td>bacterial wilt pathogen</td>
<td>Jaynes et al., 1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><em>Pseudomonas solanacearum</em></td>
<td></td>
</tr>
<tr>
<td>barley α-thionin</td>
<td>tobacco</td>
<td>20 ng/mg leaf protein</td>
<td><em>Pseudomonas syringae pv syringae</em></td>
<td>Carmona et al., 1993</td>
</tr>
</tbody>
</table>

The yeast strain is able to make the proper post-translational modifications on expressed proteins which is imperative to authenticate the mature protein product (Eckart and
Bussineau, 1996; Romanos et al., 1992). Proper post-translational processing of proteins lends to the biological activity, solubility, biodistribution, circulatory half-life and stability of the expressed foreign protein (Eckart and Bussineau, 1996). Also the secretion of properly folded proteins is imperative for the maintenance of biological activity, and is one of the more influential factors favouring yeast as a preferred host for heterologous protein expression (Romanos et al., 1992; Eckart and Bussineau, 1996).

*S. cerevisiae*, commonly known as baker’s yeast has achieved GRAS (generally recognized as safe) status, and is therefore a recognized food organism, contributing to it being an ideal system for the production of food and pharmaceutics (Gellisen et al., 1992; Gellisen and Hollenberg, 1997).

### 1.6.2 Expression and secretion of heterologous proteins in yeast

A yeast expression system has often been used in the production of heterologous proteins that are unavailable from natural sources, either due to inaccessibility or low purification yields from these natural sources. Also these proteins could be specifically designed proteins with no natural source. This is advantageous in that structural and functional studies can be carried out on the relevant protein with objectives like greater understanding and enhancement of structure and function.

For the expression and secretion of foreign protein in yeast, it is imperative that the appropriate system is chosen, in order to successfully achieve the production of biologically active proteins in high quantities. Many vectors are available for heterologous protein expression in yeast, but the most commonly used vectors are based on the yeast multicopy 2μm 6.3 kb DNA circle is *S. cerevisiae*. The 2μm plasmid contains an autonomous replication sequence that functions as the origin of replication, independent of the yeast chromosome (Romanos et al., 1992). The vectors are generally yeast-*E. coli* shuttle vectors. Yeast expression vectors require effective and appropriate promoters, secretion signal peptides, and transcriptional terminators. For selection of transformants in
yeasts, auxotrophic mutants are used that contain yeast selectable markers, e.g. \textit{LEU2}, and \textit{URA3}, which confer auxotrophy for leucine and uracil, respectively. \textit{LEU2-d} and \textit{URA3-d} are truncated promoter variants of \textit{LEU2} and \textit{URA3}, respectively, and are therefore poorly expressed which results in gives higher copy numbers in plasmids expressing the truncated genes (Loison \textit{et al.}, 1989).

Factors contributing to efficient transcription of foreign genes are: (1) cDNAs of the desired protein under yeast promoter control as was shown by the production of leukocyte \textalpha-interferon (Hitzeman \textit{et al.}, 1981); and, (2) yeasts transcriptional terminators which ensure efficient mRNA 3’ end formation and consequent maximal expression (Zaret and Sherman, 1982).

The most frequently used signal sequence that directs secretion of heterologous proteins in yeast is the preproregion from the yeast mating factor \textalpha 1 (MF\textalpha 1) (Romanos \textit{et al.}, 1992). MF\textalpha 1 prepro signal sequence is often used with the MF\textalpha 1 promoter. MF\textalpha 1 codes for the 165 residue prepro-\textalpha-factor, which comprise the 19 residue pre signal sequence and a 64 residue proregion. At the carboxyl end of the pro region is a LYS-ARG Kex2 protease cleavage sequence at which point the foreign protein is cleaved from the signal peptide, during its export through the Golgi apparatus (Reichhart \textit{et al.}, 1992).

Studies done on cationic antimicrobial peptides to understand their mode of action and structure-function relationships, requires sufficient amounts of peptide. Often the extraction of naturally occurring antimicrobial peptides from the source is a tedious and difficult process which also generates low yields. Chemical synthesis of antimicrobial peptides can be a practical alternative, but it has also proven to be expensive. For these reasons, there has been a preference for the development of biological expression systems for the facile production of these cationic antimicrobial peptides.

There are several examples of the use of yeast expression vectors for the production of cationic antimicrobial peptides. Insect defensin A, which is a 40 residue peptide, containing 6 cysteines engaged in 3 intramolecular disulfide bonds (Lambert \textit{et al.}, 1989),
has been the first reported cationic antimicrobial peptide to be expressed efficiently, and secreted in a yeast expression system. The defensin A peptide was expressed in frame with the MFα1 leader sequence under the transcriptional control of the MFα1 promoter and the phosphoglycerate kinase (PGK) terminator (Reichhart et al., 1992). This study emphasized the importance of the use of an intact signal sequence for the secretion of biologically active peptide, which reinforces the expression of biologically active leech hirudin with the use of the MFα1 prepro sequence (Loison et al., 1988).

Because the expression of insect defensin A in a yeast expression/secretion system, the radish seed cationic antifungal peptide, Rs-AFP2 has been produced in a similar expression system, and it has also been secreted in a biologically active and correctly processed form (Vilas Alves et al., 1994). Rs-AFP2 contains 4 intramolecular disulfide bonds. This study has also supported the suggestion that the MFα1 pro sequence is an important requirement for peptide secretion, and it is assumed that this is due to the pro-domain facilitating correct folding of the mature peptide (Vilas Alves et al., 1994). Mutational analysis of Rs-AFP2 was also performed using the polymerase chain reaction-based-site-directed mutagenesis of the Rs-AFP2 gene and yeast as the expression system. This was based on the same expression system used in the production of native Rs-AFP2. In total 19 correctly processed Rs-AFP2 variants were produced in this way (De Samblanx et al., 1997). The amount of Rs-AFP2 produced heterologously in the yeast system afforded the ability to determine Rs-AFP2 variants with enhanced antifungal activity, and to visualize these variants in three-dimensional representation, in order to perceive structural changes that affected enhanced bioactivity (De Samblanx et al., 1997).

The fruit fly, Drosophila, produces drosomycin, a potent 44 residue, cysteine-rich antifungal peptide (Fehlbaum et al., 1994). Drosomycin forms 4 intramolecular disulfide bridges paired identically to those found in plant defensins (Fehlbaum et al., 1994). The 4 disulfide bonds induces the highly compact structure of drosomycin, thus making the molecule resistant to proteases and heat treatment. Isolation of acceptable amounts of drosomycin from the tiny fruit fly has proved difficult (Michaut et al., 1996). A cDNA of drosomycin was therefore expressed in S. cerevisiae, and the purified recombinant peptide
displayed the same chromatographic behavior and biological activity as the natural peptide (Michaut et al., 1996). Also, over-expression of the Kex2 protease increased the yield of fully processed drosomycin in the yeast. This successful production of drosomycin in a yeast expression system facilitated determination of an extended activity spectrum including potent activity of drosomycin against agronomically important fungal pathogens; and similarity in disulfide bridge array to another radish seed antifungal peptide, Rs-AFP1. Three dimensional structural analysis of drosomycin was also made possible because there was sufficiently high expression of the peptide in the yeast system (Michaut et al., 1996).

The bacteriocin, pediocin PA-1 was cloned into a laboratory strain of the yeast S. cerevisiae Y294 (Schoeman et al., 1999). Pediocin PA-1 has been studied and shown to display food biopreservation qualities (Yousef et al., 1991). The pedA gene coding for pediocin PA-1 produced by Pediococcus acidilactici was expressed in S. cerevisiae Y294 under the control of the alcohol dehydrogenase I gene promoter and terminator, and secretion of the pediocin was directed by the Mfa1 secretion signal sequence (Schoeman et al., 1998). The recombinant pediocin PA-1 displayed the same activity spectrum as the naturally produced pediocin, which suggested that there was no alteration of the peptide by the yeast host strain (Schoeman et al., 1999). This study is an example of the use of antimicrobial peptides in creating bactericidal strains of S. cerevisiae for use as biopreservatives, rather than using chemical preservation methods, in the production of yeast-fermented food and beverages e.g., wine and bread. The development of the bactericidal yeast strain expressing antimicrobial peptides can be added to the growing list of relevant applications of antimicrobial peptides.

1.7 The antifungal peptide, ESF1

Providing disease resistance in crop plants has always been the major goal of plant biotechnology. Resistance to bacterial and/or fungal pathogens will contribute to a superior plant and increased productivity, which explains the heightening trend in the design of potential plant pathogen-resistant gene products. Antimicrobial peptides with their wide...
spectrum of activity are a good source on which to base synthetically produced peptide variants.

ESF1 is a designed synthetic peptide, mimicking the charge distribution and amphipathic α-helical structure of magainin, pGLa (Soravia et al., 1988, cited by Powell et al., 1995). ESF1 differs from pGLa in that it has a different amino acid sequence and is one amino acid shorter. This 20 amino acid, 2.052 kDa ESF1 peptide, is a member of a series of pGLa-based variants, chemically synthesized for the specific purpose of optimizing its desired activity as a gene product prior to cloning it into a plant (Powell et al., 1995). Significantly high activity has been reported for ESF1 against important fungal pathogens like Fusarium oxysporum f.sp lycopersici (Powell et al., 1995) and Fusarium oxysporum f.sp cubense race 4 (Dykes et al., 1998), the wilt-causing fungal pathogens in tomato and banana crop plants, respectively. Modifications of the ESF1 peptide’s sequence that encouraged the formation of a tighter α-helical structure seemed to increase the minimum inhibitory activity of the peptide (Dykes et al., 1998). Studies carried out on other ESF1 analogs, show that, elimination of positively charged residues destroys bioactivity, decrease in size of ESF1 length can cause significant reduction in bioactivity, and that altering positive charge density results in modest decreases in bioactivity (Powell et al., 1995). The ESF1 peptide and its analogues have all been chemically synthesized and therefore its stability if it is produced within a biological system, has not been assessed.

In this study we attempt to synthesize, clone and express ESF1 in a heterologous yeast expression system to ascertain if the peptide retains its inhibitory activity in a biological system. Also, the economic feasibility of producing peptides in biological expression systems outweighs chemical production of the peptide, and if so, will therefore also provide an alternative production method when large amounts of peptide are required for analysis.
CHAPTER TWO
MATERIALS AND METHODS
2.1 Strains, plasmids and culture conditions

The strains and plasmids used in this study appear in table 3. *E. coli* strains HB101, and JM103 were cultured in Luria-Bertani (LB) medium (Sambrook *et al.*, 1989) with vigorous agitation at 37°C. *Carnobacterium mobile* was grown in brain-heart-infusion (BHI) broth (Biolab, Midrand, Gauteng) at 30°C. BHI 0.7% agar was used as the overlaying medium in the spot-on-lawn assays, while BHI agar (Biolab) formed the bottom layer agar in the same assay. Ampicillin (Roche Biochemicals, Midrand, Gauteng) was the supplementing antibiotic added to LB media to a final concentration of 100 μg/ml, to select for *E. coli* ampicillin-resistant plasmid-containing colonies.

The yeast *S. cerevisiae* was cultured in yeast peptone dextrose (YPD) media (Ausubel *et al.*, 1992). Yeast selective media, known as synthetic complete (minimal) media (SCD) containing yeast nitrogen base without amino acids (Difco, Detroit, Michigan), 20% glucose (Associated Chemical Enterprises, Glenvista, Gauteng), and yeast dropout mix (Ausubel *et al.*, 1992) was used in yeast recombinant selection. SCD was used with uracil (Sigma Chemical Company, St. Louis, Missouri), i.e. SCD *ura* for the selection of non-transformants, and without uracil, i.e. SCD *ura* for the selection of the yeast recombinants containing the pTG3828 and pTGESF1 hybrid plasmids.

2.2 DNA manipulations and transformations

2.2.1 DNA isolations

Plasmid DNA was prepared from *E. coli*, using the alkali lysis method (Sambrook *et al.*, 1989) for mini preparations of DNA while for large scale DNA purification, the Nuclebond AX Kit (Macherey-Nagel, Duren, Germany) was used. Yeast DNA was isolated according to the total DNA isolation method outlined by Ausubel *et al* (1992).
Table 3 List of strains and plasmids used in this study

<table>
<thead>
<tr>
<th>Strain or plasmid</th>
<th>Relevant characteristics</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli JM103</td>
<td>(p(Lac-Pro), supE, thi, endA, sbcB15, strA, rk, mk', If tra Δ36, Pro AB', lacR, lacZ ΔM15)</td>
<td>Messing and Viera, 1982</td>
</tr>
<tr>
<td>E. coli HB101</td>
<td>supE44 hsdR20(tsr, m) recA13 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 met-1</td>
<td>Sambrook et al., 1989</td>
</tr>
<tr>
<td>S. cerevisiae</td>
<td>MATa, ura3-Δ5, leu2-3, -112, his, pra1, prb1, prc1, cps1</td>
<td>Shuller and Entian, 1988</td>
</tr>
<tr>
<td>C. mobile</td>
<td>indicator organism</td>
<td>this lab</td>
</tr>
<tr>
<td>pUC18</td>
<td>ampR, lacZ, lacI, 2.69 kb</td>
<td>Sambrook et al., 1989</td>
</tr>
<tr>
<td>pVD4</td>
<td>pBluescript with MFal promoter sequence, MFal prepro sequence, and insect defensin A cloned in frame with MFal pro sequence</td>
<td>from W. F. Broekaert</td>
</tr>
<tr>
<td>pTG3828</td>
<td>E. coli i yeast cloning vector</td>
<td>Achstetter et al., 1992</td>
</tr>
<tr>
<td>pUC18SF1</td>
<td>pUC18 containing ESF1 gene</td>
<td>this study</td>
</tr>
<tr>
<td>pVD18SF1</td>
<td>pVD4 containing ESF1 gene in place of insect defensin A</td>
<td>this study</td>
</tr>
<tr>
<td>pTG18SF1</td>
<td>pTG3828 containing MFal promoter and prepro sequence in frame with ESF1 gene</td>
<td>this study</td>
</tr>
</tbody>
</table>

2.2.2 Agarose gel electrophoresis

DNA samples were electrophoresed on horizontal agarose gels at 90V for 1.5 hours, and stained with ethidium bromide at a final concentration of 0.5 µg/ml, and viewed under UV light. RNA samples were electrophoresed on 1.5% formaldehyde agarose gels (http://s27w007.pswfs.gov/Protocols/northern_blotting.html), at 60V for 3 hours, and also visualized under UV light with ethidium bromide staining. Low melting temperature agarose (FMC Bioproducts, Rockland, Maine) was used when DNA fragments were required to be recovered after electrophoresis.
2.2.3 Recovery of DNA from agarose gels

DNA samples were separated by electrophoresis on 1% low melting temperature agarose and viewed under UV light. The band of interest was excised with a gel cutter. Recovery of DNA from the excised fragment was accomplished using the Nucleospin Extract kit (Macherey-Nagel, Duren, Germany) from the HindIII/BamHI digested pVD4 and the Sall/BamHI digested pVDESFl. For isolation of the constructed ESFl gene from low melting temperature agarose, the Sephaglas Bandprep kit (Amersham-Pharmacia, Johannesburg, Gauteng) was used.

2.2.4 Enzymes

All restriction enzymes digests were carried out at 37°C from 3 hours to overnight to ensure complete digestion of DNA. T4 DNA ligase (Promega Corporation, Madison, Wisconsin) reactions were carried out between 16°C to 20°C, according to manufacturer’s instructions.

2.2.5 Transformation

E. coli cells were first made competent by the calcium chloride method (Sambrook et al., 1989), and then the transformation was carried out using the general procedure outlined by Sambrook et al. (1989). For transformation in the yeast, S. cerevisiae, the high efficiency lithium acetate method was used (Gietz and Shiestl, 1991).

2.3 Synthetic ESFl gene assembly

The five oligonucleotides comprising the ESFl gene: VV1, 5' ATG GCT TCT CGT GCT GCT GGT CTG GCT GCT CG 3'; VV2, 5' TCT GGC TCG TCT GGC TCT GCG TGC 37
TCT GTA AT 3'; VV3, 5' GAC CAG CAG CAT GAG CCA T 3'; VV4, 5' ACG ACG CAG ACG AGC AGC AGC AGC AGC CA 3'; and VV5, 5' CTAGA TTA CAG AGC 3' (the double underlined sequences indicate the XbaI restriction enzyme recognition sequence) were added together at a concentration of 100 picomoles each and heated to 95°C for 15 minutes. The oligonucleotide mixture was then allowed to cool to room temperature to facilitate annealing of the complementary oligonucleotides, followed by overnight ligation at 16°C.

2.4 Cloning of the assembled ESFl gene into pUC18

The assembled ESFl gene was cloned into the HincII (Roche Biochemicals) and XbaI (Roche Biochemicals) sites of pUC18. Blue/white colony selection on LB agar supplemented with 100 µg/ml ampicillin, 0.1M IPTG (Roche Biochemicals) and 80 µg/ml X-gal (Roche Biochemicals) was used to select for putative pUC18/ESF1 recombinant colonies.

2.5 Cloning of the ESFl gene into pVD4

The pUC universal reverse primer (Roche Biochemicals), and the forward primer VV-GEN1 (5' AAT AAG CTT GGA CAA GAG AAT GGC TTC TCG TGC TGC TGG T 3') were used for to amplify the ESFl gene fragment from the pUCESF1 recombinant plasmid. The VV-GEN primer composed of the 3' end of the MFa1 pro sequence as the first 19 nucleotides, and the other 21 nucleotides consisted of the 5' end of the ESFl gene sequence. Thirty cycles of PCR was carried out using the following conditions on a Perkin Elmer GeneAmp PCR System 2400 (Perkin Elmer Applied Biosystems, Foster City, California): first 2 amplification cycles consisted of denaturation at 94°C, annealing at 37°C, and elongation at 72°C; while the next 25 amplification cycles consisted of denaturation at 94°C, annealing at 55°C, and elongation at 72°C. The PCR amplification product and the pVD4 vector were restricted with HindIII (Roche Biochemicals) and
Table 4 Components of the PCR reaction mixture for amplification of the ESF1 gene from the recombinant pUC/ESF1 vector

<table>
<thead>
<tr>
<th>Reagents</th>
<th>1.5mM</th>
<th>2mM</th>
<th>3mM</th>
<th>3.5mM</th>
<th>4mM</th>
<th>1.5mM</th>
<th>1.5mM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MgCl₂</td>
<td>1.5M</td>
<td>6</td>
<td>8</td>
<td>12</td>
<td>14</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td>MgCl₂</td>
<td></td>
<td></td>
<td></td>
<td>to</td>
<td>4mM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR nucleotide mix</td>
<td>200μM</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>PCR reaction buffer</td>
<td>1x</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>10xPCR reaction buffer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pUC universal reverse primer</td>
<td>300nM</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>pUCESF1 forward primer</td>
<td>300nM</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>pMal-p2 DNA</td>
<td>&lt;1μg</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>pMal-p2 DNA</td>
<td>&lt;1μg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.5</td>
</tr>
<tr>
<td>Sterile millipore H₂O</td>
<td>-</td>
<td>79</td>
<td>77</td>
<td>73</td>
<td>71</td>
<td>69</td>
<td>79.5</td>
</tr>
<tr>
<td>Volumes in μl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Volumes in \( \mu l \)

<table>
<thead>
<tr>
<th>Reagents</th>
<th>[Final]</th>
<th>1.5mM</th>
<th>2mM</th>
<th>3mM</th>
<th>3.5mM</th>
<th>4mM</th>
<th>1.5mM</th>
<th>1.5mM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
<td>MgCl(_2)</td>
</tr>
<tr>
<td>no</td>
<td>pMal-p2</td>
<td>template</td>
<td>DNA</td>
<td>DNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taq polymerase</td>
<td>0.5U</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Volume</td>
<td>Total</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>
BamHI (Roche Biochemicals), and were ligated with T4 DNA ligase. Following transformation, putative pVD4 recombinants containing the ESF1 gene in place of the insect defensin A gene were selected on LB agar supplemented with ampicillin.

2.6 Cloning of the ESF1/MFa1 expression cassette into pTG3828

The yeast/E. coli shuttle vector, pTG3828, was cleaved with SalI (Roche Biochemicals) and BglII (Roche Biochemicals) and ligated to the SalI/BamHI digested pVDESF1 fragment containing the ESF1/MFa1 gene expression cassette. Yeast colonies transformed with pTG3828 containing the ESF1/MFa1 expression cassette were selected on SCD ura medium.

2.7 Verification of recombinant plasmids

2.7.1 Southern Hybridization

Southern hybridization was carried out using the general method of Sambrook et al. (1989). A DIG 3' end-labeling kit (Roche Biochemicals) was used to digoxigenin label oligonucleotide probes. Detection of the hybridized probe was accomplished with the DIG Detection kit (Roche Biochemicals). Both 3' end-labeling and detection were done according to manufacturer’s instructions.

To determine the pVDESF1 clones by Southern hybridization, a hybridization temperature of 55°C was used with digoxigenin-labeled VV3 as probe. Digoxigenin-labeled probe proMF (5' ACA GCA CAA ATA ACG GG 3') was used at a hybridization temperature of 42°C for detection of pTGESF1, isolated from E. coli and yeast transformants, and ESF1 cDNA produced by reverse transcriptase PCR from pTGESF1, isolated from yeast transformants. The probe proMF hybridizes to part of the MFa1 pro
sequence.

2.7.2 Restriction analysis

Restriction digest of pUCESF1 putative recombinants with PstI (Roche Biochemicals) and BamHI was carried out to ascertain the insertion of the 63 bp ESF1 gene in pUC18. Restriction digest by KpnI of pVDESF1 recombinants was carried out to determine replacement of insect defensin A by the ESF1 gene in pVD4 (figure 5). A SalI and ClaI (Roche Biochemicals) restriction digest of pTGESF1 recombinants was also done to verify the presence of the ESF1/MFaI gene expression cassette in pTG3828 (figure 8).

2.7.3 Polymerase chain reaction (PCR)

To determine the presence of the ESF1/MFaI gene expression cassette in pTGESF1, amplification of part of the MFaI pro sequence and ESF1 was carried out. The proMF forward primer and PGKrev reverse primer (5' GCA ACA CCT GGC AAT TC 3'), which anneals to the 5' end of the PGK terminator sequence were used. The PCR profile for 25 cycles was as follows: denaturation at 94°C, annealing at 37°C, and elongation at 72°C.

2.7.4 DNA Sequencing

DNA sequencing of recombinant plasmid DNA was performed by the dideoxy chain termination method outlined by Sanger et al. (1977), using the Sequenase™ Version 2.0 DNA sequencing kit (USB-Amersham Life Sciences, Cleveland, Ohio).
2.8. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)

A 12% non-denaturing acrylamide gel (30% T; 1% C) was used to separate the restricted DNA fragments of the pUCESF1 PstI/BamHI digestion. The gel was electrophoresed at 100V for 45 minutes, stained with ethidium bromide and visualized under UV light.
Table 5 Components of the PCR reaction mixture for amplification of the *ESF1* gene from the recombinant vector pTGESF1.

<table>
<thead>
<tr>
<th>Reagents</th>
<th>[Final]</th>
<th>1.5mM</th>
<th>2.5mM</th>
<th>3.5mM</th>
<th>4.5mM</th>
<th>1.5mM</th>
<th>1.5mM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MgCl₂</td>
<td>MgCl₂</td>
<td>MgCl₂</td>
<td>MgCl₂</td>
<td>MgCl₁</td>
<td>MgCl₁</td>
</tr>
<tr>
<td>10xPCR reaction buffer</td>
<td>1x</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>25mM MgCl₂</td>
<td>1.5mM</td>
<td>6</td>
<td>10</td>
<td>14</td>
<td>18</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>to 4mM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR nucleotide mix</td>
<td>200μM</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>each</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>proMF forward primer</td>
<td>300nM</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>pGK-rev reverse primer</td>
<td>300nM</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>A5 yeast transformant DNA</td>
<td>&lt; 1μg</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>pTGESF1 DNA</td>
<td>&lt; 1μg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.5</td>
<td>-</td>
</tr>
<tr>
<td>Taq polymerase 1U/μl</td>
<td>0.5U</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Sterile millipore H₂O</td>
<td>-</td>
<td>79</td>
<td>75</td>
<td>71</td>
<td>67</td>
<td>79</td>
<td>79.5</td>
</tr>
<tr>
<td>Total Volume</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>
2.9 Reverse Transcriptase PCR (RT-PCR)

Yeast total RNA was extracted from the recombinant logarithmic phase *S. cerevisiae* culture by treating the cells with Zymolyase (ICN Biomedicals Incorporated, Aurora, Ohio) to form spheroplasts, followed by lysing the cells by vortexing them in the presence of acid-washed glass beads, and then repeating a phenol/chloroform extraction to purify the RNA (Ausubel *et al.*, 1992). An amount of 0.25 μg of VV3 oligonucleotide DNA was added to 0.5 μg yeast total RNA, and the nucleic acids were denatured at 95°C for 10 minutes. To this mixture, AMV reverse transcriptase (Promega Corporation) was added and the reverse transcription reaction was carried out at 42°C for 1 hour. Lithium chloride was then added to a final concentration of 2M, along with 100% ethanol and the mixture was incubated at 70°C for another hour, to precipitate the DNA. The precipitated DNA was centrifuged, washed in 70% ethanol and resuspended in 10μl of sterile distilled water. A 20μl PCR reaction using VV3 oligonucleotide as the reverse primer and proMF as the forward primer was performed to amplify the 5’ region of the *ESF1* gene and part of the *MFal pro* sequence from the cDNA. The PCR conditions were as follows for 25 cycles: denaturation at 94°C, annealing at 37°C and elongation at 72°C.

2.10 Purification of ESF1 peptide from the yeast pTGESF1 transformant culture supernatant

A 10ml overnight culture of the selected pTGESF1 yeast transformant was used to inoculate 500ml of SCD<sup>ara</sup> yeast selective media. After 48 hours incubation at 30°C with vigorous shaking, the culture was centrifuged at 12000×g for 30 minutes at 4°C. Purification was carried out on a Perkin Elmer series 200 high pressure liquid chromatography pump (Perkin Elmer Applied Biosystems). The supernatant containing the ESF1 peptide was acidified to pH 3 with glacial acetic acid and applied onto a preparative Bondapak-C<sub>18</sub> (Waters RCM 25×10) HPLC column (Millipore, Bedford, Massachusetts) equilibrated with acidified water. Stepwise removal of unwanted media
components and proteins was conducted by carrying out 2,10 minute elution steps at 10% and 30%.

Table 6 Components of the PCR reaction mixture for amplification of the ESFl gene from cDNA of the ESFl gene sequence from the vector pTGESF1 isolated from yeast transformant A5.

<table>
<thead>
<tr>
<th>Reagents</th>
<th>[Final]</th>
<th>pTG3828 cDNA</th>
<th>pTGESF1 cDNA</th>
<th>positive control pVDESF1 DNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>10xPCR reaction buffer</td>
<td>1X PCR reaction buffer</td>
<td>2μl</td>
<td>2μl</td>
<td>2μl</td>
</tr>
<tr>
<td>containing MgCl₂</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MgCl₂</td>
<td>1.5mM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>proMF forward primer</td>
<td>300nM</td>
<td>1μl</td>
<td>1μl</td>
<td>1μl</td>
</tr>
<tr>
<td>VV3 reverse primer</td>
<td>300nM</td>
<td>1μl</td>
<td>1μl</td>
<td>1μl</td>
</tr>
<tr>
<td>PCR nucleotide mix</td>
<td>200μM each</td>
<td>0.4μl</td>
<td>0.4μl</td>
<td>0.4μl</td>
</tr>
<tr>
<td>sterile millipore H₂O</td>
<td>-</td>
<td>5.35μl</td>
<td>5.35μl</td>
<td>15.35μl</td>
</tr>
<tr>
<td>template cDNA from RT reaction</td>
<td>&lt;0.75μg</td>
<td>10μl</td>
<td>10μl</td>
<td>1μl</td>
</tr>
<tr>
<td>Taq polymerase</td>
<td>0.25U</td>
<td>0.25μl</td>
<td>0.25μl</td>
<td>0.25μl</td>
</tr>
<tr>
<td>Total volume</td>
<td>20μl</td>
<td>20μl</td>
<td>20μl</td>
<td>20μl</td>
</tr>
</tbody>
</table>
acetonitrile in acidified water, and a linear gradient 30-40% acetonitrile elution over 5 minutes, all at a flowrate of 4ml/min, until no more proteins were detected. Synthetic ESF1 peptide applied to a C18 analytical Brownlee column (Applied Biosystems, Foster City, California) eluted at 41.883% acetonitrile in acidified water (figure 13), following a linear elution gradient at 10-60% acetonitrile in acidified water, over 50 minutes at a flow rate of 1ml/min. Therefore, the 40-50% acetonitrile in acidified water elution gradient carried out over 30 minutes at a flow rate of 4ml/min was collected, freeze dried, and reconstituted in 0.2ml 0.1% trifluoroacetic acid (TFA). This 0.2ml fraction was then applied on the C18 analytical Brownlee column and the 41-44% acetonitrile in acidified water fraction was collected, following the same linear acetonitrile gradient used in purification of the synthetic ESF1 peptide above.

2.11 Bioassays

The spot-on-lawn assay (Hastings et al., 1991) was used to determine presence and activity of ESF1 peptide. C. mobile was used as the indicator organism since ESF1 was reported to have a low MIC of 2.5 nM against the bacterium (Dykes et al., 1998).

2.12 Tricine SDS-PAGE

A separating layer (10% T, 3% C), spacer layer (10% T, 3% C) and stacking layer (4% T, 3% C) tricine polyacrylamide gel (Schagger and von Jagow, 1987) was used to detect the presence of ESF1 peptide in the analytical column, lyophilized, purified fraction. Electrophoresis was performed at 30V for 2.5 hours. The gel was first fixed in 10% formaldehyde for 1 hour, and then washed for a further 1 hour with 5 changes of distilled water. After washing, the gel was stained in Coomassie Brilliant Blue R-250 (Sigma ) for 1 hour and left in destain solution (7% acetic acid, 5% methanol) overnight. A low range protein marker (Promega Corporation) was also electrophoresed on the gel to determine the approximate sizes of the protein bands in the gel.
2.13 Electroblotting of protein onto polyvinylidene fluoride (PVDF) membrane

Electroblotting of the proteins on the tricine gel was performed using the Mini Transblot Cell (Biorad, Hercules, California) electroblotting apparatus for 60 minutes at 90V in electrotransfer buffer (10mM 3- cyclohexylamino- 1- propanesulfonic acid (CAPS), 10% methanol, 0.1mM thioglycollic acid, pH 11 ). The method used was described by Matsudaira (1987) with minor modifications. A 0.2 micron Transblot Transfer Medium (Biorad) PVDF membrane was the blotting membrane of choice since its small pore size facilitates efficient transfer of small peptides like ESF1.

2.14 Amino acid sequencing

N-terminal amino acid sequence analysis of an excised band from the PVDF membrane was analyzed on a Perkin Elmer Applied Biosystems Procise 491 (Applied Biosystems) automated protein sequencer using the pulsed liquid PVDF peptide method (Hewick et al., 1981) at the University of Natal Molecular Biology Unit.

2.15 Electro Spray Mass Spectrometry (ES-MS)

Mass spectrometric analysis of 20μl of the crude preparative column fraction of the pTGESF1 transformed yeast culture supernatant was conducted on a model API III quadruple mass spectrometer equipped with an Ionspray source (Sciex, Thornhill, Canada) at the Center for Mass Spectrometry.
2.16 Purification of antibodies produced in chickens against the synthetic ESF1 peptide

2.16.1 Immunization of chickens

Laying hens (Amber-link) received an initial injection intramuscularly at 2 sites in their large breast muscles with 200μg ESF1 peptide. The peptide was suspended in phosphate-buffered saline (PBS; 1ml), and emulsified with Freund’s complete adjuvant (Sigma) in a 1:1 (v/v) ratio. After the initial injection the hens received a further 3 injections at the same dose in Freund’s incomplete adjuvant, fortnightly, in the same manner. Eggs of immunized chickens were collected daily over the immunization period, labeled and stored at 4°C, until processed for isolation of IgY antibodies.

2.16.2 Isolation of IgY antibodies from chicken egg yolks

The method of Polson and von Wechmar (1980), was used to extract IgY from the egg yolks of immunized chickens. Eggs collected on the fifth day of every week during immunization were used in the IgY isolation procedure. The concentration of IgY was measured at an absorbance of 280 nm, and protein content calculated as described by Coetzer (1985). An enzyme-linked immunosorbent assay (ELISA) was performed to determine the presence of anti-ESF1 antibodies. Synthetic ESF1 peptide at a concentration of 1μg/ml in PBS was used to coat the multititre plate (Nunc maxisorb, Amersham- Pharmacia), overnight at 4°C. A synthetic leucocin A peptide (Hastings et al., 1991) at the same concentration was used to coat a duplicate plate as a control for the specificity of anti-ESF1 antibodies. Dilutions of the antibodies purified from eggs collected at different intervals during the immunization program, as well as, non-immune IgY at concentrations of 500 μg/ml, 100 μg/ml, 50 μg/ml, and 10 μg/ml, were allowed to incubate in the antigen-coated microtitre plates. Incubation was performed for 2 hours at 37°C. Binding of the primary antibodies was visualized by incubation
with rabbit anti-IgY-HRPO conjugate (Jackson Laboratories, USA), and ABTS (Roche Biochemicals) as outlined by Coetzer et al (1991).

2.16.3 Purification of anti-ESF1 antibody

To purify anti-ESF1 antibodies, affinity chromatography was employed. Approximately 4mg of synthetic ESF1 peptide was immobilized on a 2ml aminolink column using the Immunopure Ag/Ab Immobilization Kit (Pierce, Rockford, Illinois) as per the manufacturer’s instructions. A volume of 125ml of isolated IgY was circulated through the aminolink-peptide column overnight at a flow rate of 10ml/h. Following this the affinity purification protocol was performed as per manufacturer’s instructions. Elution of the antibody was achieved using 0.1M glycine-HCl, pH 3, and the absorbance was measured at 280nm to determine in which fractions the antibody eluted from the column. The fractions with the highest protein concentrations were pooled and another ELISA performed to ascertain the presence of anti-ESF1 antibody in the Immunoaffintiy-purified fractions.

2.17 Western dot blot analysis of pTGESF1 transformant culture supernatant

Synthetic ESF1 peptide, C18 preparative and analytical HPLC column freeze dried fractions, and leucocin A peptide were spotted on to Hybond-C nylon membrane (Amersham Life Sciences, Cleveland, Ohio), and left to air dry for 30 minutes. The available sites on the membrane were blocked for 1 hour with 5% non-fat milk in Tris buffered saline (TBS) and washed 3 times for 5 minutes each with TBS. Next, the membrane was incubated for 2 hours with the affinity purified anti-ESF1 antibody at a concentration of 25 μg/ml in 0.5% BSA-TBS. The membrane was washed again with TBS (3 times, 5 minutes), and incubated for another 1 hour in alkaline-phosphatase linked rabbit anti-chicken IgG (Sigma) in 0.5% BSA-TBS. This antibody cross-reacts with chicken IgY. Following the final TBS wash (3 times, 5 minutes) the membrane
was allowed to react in the dark with the BCIP/NBT substrate (Sigma) dissolved in distilled water, until dots appeared on the membrane against a lightly stained background. The dot blots were stored between sheets of filter paper in the dark until photographed.
CHAPTER THREE
RESULTS AND DISCUSSION
3.1 Assembly of *ESF1* gene sequence and its cloning into pUC18

The VV1 and VV2 oligonucleotides comprised the 5' to 3' strand of the *ESF1* gene, while the VV3, VV4 and VV5 oligonucleotides comprised the 3' to 5' strand of the *ESF1* gene (figure 3). VV5 was designed with a *XbaI* overhang at the 3' end, of the gene to facilitate easy cloning into pUC18. The intention of cloning into pUC18 was to make the *ESF1* gene sequence easily accessible for manipulation in further cloning experiments since pUC18 is a high copy number plasmid and therefore ensures provision of numerous copies of the *ESF1* gene sequence. Polyacrylamide gel electrophoresis of *BamHI/PstI* restricted putative pUC*ESF1* recombinants verified the insertion of the constructed *ESF1* gene fragment due to the presence of an expected 78 bp restriction product on the agarose gel (figure 4).

![Diagram of oligonucleotide assembly](image)

*Figure 3* Construction of the *ESF1* gene. The five oligonucleotides VV1, VV2, VV3, VV4 and VV5 were designed to comprise the *ESF1* gene sequence. Annealing allows the joining of the complementary oligonucleotides VV1 and VV2 of the 5’ to 3’ strand to VV3, VV4 and VV5 of the 3’ to 5’ strand, while ligation facilitates joining of the VV1 to VV2, VV3 to VV4, and VV4 to VV5 oligonucleotides.

3.2 Construction of the pVDESF1 recombinant vector

For the efficient expression of the *ESF1* gene and secretion of ESF1 peptide, the Mfas1 promoter that drives transcription of the gene and the Mfas1 prepro sequence which directs secretion of the peptide is required. This Mfas1 promoter and prepro sequences are
Figure 4 12.5% Polyacrylamide gel of putative pUC/ESF1 clones restricted with BamHI/PstI to give a 78 bp fragment containing the ESF1 gene. Lanes: (1) EcoRI/HindIII digested λ-DNA; (2) pUC/ESF1 transformant 1; (3) pUC/ESF1 transformant 2.

Figure 5 pBluescript-based vector pVD4. The vector has been assembled from a basic pBluescript vector by the introduction of the MFa1 promoter and prepro leader sequences to form an expression cassette, with the insect defensin A sequence cloned in frame with the expression cassette. This will allow expression and secretion of the cloned peptide in yeast. The underlined KpnI site contained within the insect defensin A sequence is not present in the ESF1 sequence. This allows determination of the probable replacement of insect defensin A by the ESF1 gene during restriction analysis of putative pVD/ESF1 clones. The arrows indicate the site of insertion for the ESF1 gene (W.F Broekaert, personal communication).
contained as an expression cassette within the pBluescript-based vector, pVD4 (figure 5). pVD4 also contains the insect defensin A sequence cloned in frame to the pro sequence. The expression cassette has a HindIII site engineered 5' to the Kex2 protease cleavage site. This cleavage site causes separation of the ESF1 peptide from the prepro peptide once processed by the Kex2 protease. The ESF1 gene was cloned into the HindIII/BamHI sites of pVD4 therefore effectively replacing the insect defensin A gene to lie in frame with the pro sequence. PCR of the pUCESF1 recombinant produced the expected 146 bp fragment (figure 6), which after restriction with BamHI/HindIII was cloned into the pVD4 vector at the compatible sites. KpnI restriction of putative pVDESF1 recombinants should not produce a 140 bp restriction fragment since the ESF1 gene does not contain a KpnI site like the insect defensin A gene contains.

![Figure 6: Agarose gel (3%) of PCR amplification of ESF1 gene from pUCESF1 clone. Lanes: (1) 1018 bp fragment and its multimers plus pBR322 fragments; (2) pUCESF1, 1.5mM MgCl₂; (3) pUCESF1, 2mM MgCl₂; (4) pUCESF1, 3mM MgCl₂; (5) pUCESF1, 3.5 mM MgCl₂; (6) pUCESF1, 4mM MgCl₂; (7) no template, 1.5mM MgCl₂; (8) pMAL-p2, 1.5mM MgCl₂.](image)

This aided in determining whether the replacement of the insect defensin A sequence by ESF1 had taken place (figure 7). Southern hybridization (figure 7) verified the presence of ESF1 in the pVDESF1 recombinant DNA.
Figure 7 Agarose gel (left) and corresponding Southern blot (right) of pVD4/ESF1 (KpnI) putative hybrids. Lanes: (1) 1018 bp fragment and its multimers plus pBR322 fragments; (2) pVD4; (3) pVD4 (KpnI); (4) transformant 6b; (5) transformant 7b; and (6) transformant 8b. Digoxigenin-labeled probe VV3, which hybridizes to ESF1 was used at a hybridization temperature of 55°C.

Figure 8 Yeast/E. coli shuttle vector pTG3828. The multiple cloning site contains the SalI and BglII sites indicated by arrows at which the MFα1/ESF1 gene expression cassette can be cloned. The expression cassette will then be flanked at the 3' end by the PGK transcriptional terminator thus providing stability to the MFα1 prepro leader and ESF1 mRNA strand. The underlined ClaI site will lie 3' to the inserted expression cassette, and following cleavage of pTGESF1 DNA with SalI and ClaI, an approximate 1.3 kb fragment should be produced (Achstetter et al., 1992).
3.3 pTG3828 containing the Mfa1/ESF1 gene expression cassette isolated from E. coli transformants

pTG3828 is a yeast /E. coli shuttle vector (figure 8). This shuttle vector consists of the efficient yeast phosphoglyceratekinase (PGK) transcriptional terminator to produce more stable mRNA transcripts; an ampicillin resistance gene for selection of the plasmid in an E. coli host strain; multiple cloning site to facilitate the insertion of a promoter and coding sequence; and the URA3-d gene for maintenance of a high plasmid copy number (Loison et al., 1989). The 1296 bp Mfa1/ESF1 expression cassette from the pVDESFL recombinant plasmid was cloned into the pTG3828 vector. DNA isolated from transformants was verified as pTGESF1 recombinants by Southern hybridization (figure 9).

Figure 9 Agarose gel (left) and corresponding Southern blot of putative pTGESF1 recombinants. Lanes: (1) digoxigenin-labeled EcoRI/HindIII cleaved λ-DNA; (2) pVDESFL, (3) pTG3828; (4, 5, 6, 7, 8) putative pTGESF1 clones. Digoxigenin-labeled probe, proMF, hybridizing to the Mfa1 pro sequence, was used at a hybridization temperature of 42°C for Southern hybridization.

3.4 pTG3828 containing the Mfa1/ESF1 gene expression cassette isolated from Saccharomyces cerevisiae c13ABYS86 transformants

DNA of the yeast transformants was isolated but very low amounts were visible in the
agarose gel (figure 10), which was also indicated by faint detection of the pTGESF1 recombinant after Southern hybridization (figure 10). PCR amplification of part of the MFa1/ESF1 gene expression cassette did result in the expected amplification product of 216 bp, indicating the presence of pTGESF1 (figure 11). Isolation of DNA from the same yeast transformants was carried out in triplicate resulting in similar low yields of recombinant plasmid DNA as was shown by agarose gel electrophoresis, and DNA concentration analyses (results not shown). It is probable that the recombinant plasmid exists in low copy number within the S. cerevisiae c13ABYS86 transformation strain.

3.5 Transcription of the MFa1 prepro sequence and ESF1 gene

RT-PCR shows that transcription of the MFa1 prepro sequence and ESF1 gene does occur (figure 12). Southern hybridization (figure 12b) verified that the amplification
obtained after PCR does contain the ESFl gene sequence. Reverse transcriptase transcription of yeast total mRNA revealed no product following agarose gel electrophoresis (results not shown), therefore PCR was carried out to amplify any cDNA that was produced after the transcription reaction. The need for PCR amplification to detect the presence of cDNA suggests again the probable presence of a small amount of recombinant DNA available for transcription and subsequent translation.

3.6 Purification and detection of ESFl peptide in pTGESF1 transformant culture supernatant

The elution profile from the preparative HPLC column (figure 14a) determined a peak at the approximate retention time of synthetic ESFl peptide (figure 13), which is absent in the pTG3828 transformed culture supernatant (figure 14b). No clear peak was visible therefore a 41 to 44% acetonitrile in acidified water fraction (figure 15) from the analytical column.
Figure 12 RT-PCR of yeast total mRNA (A) and Southern blot (B) of the gel indicating mRNA transcription of the ESF1 gene. Lanes: (1) Digoxigenin-labeled EcoRI/HindIII cleaved λ-DNA; (2) 1018 bp fragment and its multimers plus pBR322 fragments; (3) pBR322 (HaeIII digested); (4) RT-PCR of pTGESF1 transformed yeast mRNA; (5) RT-PCR of pTG3828 transformed yeast mRNA; and (6) PCR of pVDESF1. Amplification products are noted for the reverse transcribed pTGESF1 transformed yeast mRNA and the positive control pVDESF1 DNA (contains recombinant Mfu1/ESF1 expression cassette).

was collected because it was at about 41.8% acetonitrile in acidified water that synthetic ESF1 eluted (figure 13). Spotting 5μl of the freeze dried HPLC analytical column fraction showed a zone of inhibition in a lawn of C. mobile seeded BHI agar (figure 16). Activity was noted only after HPLC analytical column purification which is an approximate 10 000 times concentrate of the supernatant which suggests a very small quantity of ESF1 peptide present in the supernatant of the pTGESF1 yeast transformant culture.

Tricine SDS-PAGE (figure 17) of a 10μl fraction eluted from the analytical column and freeze dried, showed an approximate 2 kDa protein whose sequence analysis revealed the presence of amino acid residues present within ESF1. Too many N-terminal amino acids were visible in each amino acid sequencing cycle to determine a proper sequence. It is possible that there are small protein fragments of around 2 kDa present in the fraction that
Antibodies against ESF1 peptide were raised, to be used in verifying the presence of ESF1 peptide in the recombinant yeast culture supernatant. Antibody production is illustrated graphically in Figure 18. Eggs from the ninth week showed the highest concentration of protein and therefore IgY isolations from eggs laid in this week were pooled together, and used in the immunooaffinity purification of anti-ESF1 antibody. The absorbance data in Figure 19, shows that the ELISA performed after immunooaffinity purification, and in particular that the lowest purified anti-ESF1 antibody dilution of 1 μg/ml shows a strong antibody-ESF1 peptide antigen reaction.
Figure 14 Elution profile of pTGESF1 (A) and pTG3828 (B) transformed culture supernatant using Bondapak-C$_{18}$ preparative HPLC column, monitored by absorbance at 220nm, using acetonitrile in acidified water as the solvent. Eluent at 30-40 minutes retention time was collected since the visible protein from the recombinant yeast culture supernatant (A) has a retention time of 33.090 minutes, which correlates with the retention time 31.883 for synthetic ESF1 peptide from a C$_{18}$ analytical HPLC column.
Figure 15 Elution profile of pTGESF1 (solid line) and pTG3828 (dotted line) transformed yeast culture supernatant using the C_{18} analytical HPLC column monitored at A_{220} using acetonitrile/acidified water as solvent. A fraction with 31-34 minutes retention time was collected, lyophilized and activity against *Carnobacterium mobile* was displayed. The peak at the retention time of 31.667 minutes is thought to represent ESF1 peptide.

Figure 16 Spot-on-lawn assay of HPLC analytical column, lyophilized fractions of pTGESF1 and pTG3828 transformed yeast culture supernatants. 5\(\mu\)l of pTGESF1 (1) and pTG3828 (2) culture preparations were spotted on brain-heart-infusion agar seeded with the indicator organism, *Carnobacterium mobile*. Only the pTGESF1 culture supernatant shows activity against the indicator bacterium.
Figure 17 Tricine (10% C; 3% T) SDS-PAGE of HPLC analytical column, lyophilized fractions of both pTGESF1 and pTG3828 transformed yeast cultures. The arrow indicates the position of the 2.052 kDa ESF1 peptide, and this band was blotted to PVDF membrane and subjected to amino acid sequencing. Lanes: (1) Promega low range protein marker, (2) Promega low range protein marker, (3) empty, (4) pTG3828 yeast culture supernatant (10μl), (5) and (6) pTGESF1 transformed yeast culture supernatant (20μl), (7) pTGESF1 transformed yeast culture supernatant (10μl).

The absorbance values for a concentration of 1 μg/ml purified anti-ESF1 antibody (figure 19) is similar to absorbance values obtained for a 100 μg/ml ESF1 antibody concentration from total IgY isolations (figure 18) from the eggs of the ninth week. These results were interpreted as an approximate 100 fold increase in the sensitivity of immunoaffinity purified anti-ESF1 antibody to ESF1 peptide compared with the antibody sensitivity for the total IgY antibody isolated using ELISA. The immunoaffintiy purification concentrated only the ESF1 peptide specific IgY antibodies. Consequently, there is removal of non-specific antibodies, and the specificity of anti-ESF1 antibody is enhanced.
Figure 18 Progress of immunization with ESF1 peptide as determined by ELISA. ESF1 peptide was coated at 1 μg/ml to microtitre plates and incubated with antibody dilutions of 500 μg/ml, 100 μg/ml, 50 μg/ml and 10 μg/ml, collected after 4 (●), 6 (■), 8 (▲), and 9 (▲), and non-immune IgY (+). Binding was visualized by incubation with rabbit anti-chicken HRPO-linked secondary antibody as described by Coetzer et al. (1991). Each point is a mean at A405 of duplicate samples.

Western dot blot analysis of the analytical column freeze dried fraction shows positively that there is ESF1 peptide present in the pTGESF1 culture supernatant (figure 20). The leucocin A (Hastings et al., 1991) control shows no binding to anti-ESF1 antibody and therefore provides evidence of the specificity of anti-ESF1 antibody. There is, although, a visible antibody binding to the preparative column freeze dried pTG3828 yeast culture supernatant fraction. The reason for this is that the preparative column fraction still contains media components such as caramelized sugar which is present as a brown residue with a high concentration of insignificant proteins, which binds the antibody non-specifically.
Figure 19 Representation of different immunoaffinity purified ESF1 IgY concentrations with ESF1 peptide as determined by ELISA. ESF1 peptide was coated at 1 μg/ml to microtitre plates and incubated with antibody dilutions of 100 μg/ml, 50 μg/ml and 10 μg/ml, and 1 μg/ml collected during immunoaffinity purification. Binding was visualized by incubation with rabbit anti-chicken HRPO-linked secondary antibody as described by Coetzer et al. (1991).

The method for purification of ESF1 peptide on the HPLC analytical column removes these contaminating media and protein components and concentrates the ESF1 peptide thus permitting a pure antibody-peptide antigen immunogenic reaction. Figure 20 shows that the brightness of the dot at position 2 (preparative column pTGESF1 culture supernatant fraction) is greater than that at position 3 (preparative column pT3828 culture supernatant fraction), which is due to binding of antibody to other media and
contaminating high concentration protein components, and to ESF1 peptide, while there is only a dot visible at position 5 (analytical column pTGESF1 culture supernatant fraction) and none visible at position 6 (analytical column pT3828 culture supernatant fraction), which is due to the presence of concentrated ESF1 peptide, and no other impurities resulting in a greater anti-ESF1 antibody/ESF1 peptide antigen immunogenic reaction.

Mass spectrometry analysis of synthetic ESF1 peptide and a 20μl preparative column freeze dried fraction reveal the presence of a peak at a 684 mass to charge (m/z) ratio for both samples (figure 21). This 684 m/z ratio equates to 2052 Da, which is the approximate size of ESF1 peptide, and thus verifies the presence of EFS1 peptide in the recombinant yeast supernatant. The peak profile of the preparative column fraction still shows a large number of impurities, which contributes to the reasoning as to why there is...
a non-specific reaction with anti-ESF1 antibody.

There was a low yield of ESF1 peptide which may have been related to the low DNA concentrations isolated from yeast transformants and low concentrations of ESF1 peptide purified from the transformed yeast culture supernatant. Frequent variation in the

Figure 21 Electro spray mass spectrometry of synthetic ESF1 peptide and a Bondapak-C18 preparative column HPLC preparation of pTGESF1 yeast culture supernatant. The 684.27 (m/z) ratio in (B, HPLC ESF1 preparation) corresponds to the 684.65 (m/z) ratio in (A, synthetic ESF1 peptide). 684 (m/z) is calculated to be 2052 Da, which reflects the ESF1 peptide mass, and this shows that ESF1 peptide is contained within preparative column fraction of the pTGESF culture supernatant.
productivity of different transformants has been noted when using 2 μm vectors, due to an unexplained variation in copy number between different transformants (Loison et al., 1989; Purvis et al., 1987). For this reason numerous transformants were screened for the recombinant pTGESF1 plasmid. All transformants seemed to contain approximately the same low amounts of recombinant plasmid DNA as can be seen in figure 10, indicated by the faint DNA bands. Repeated DNA purification of the same yeast transformants gave approximately the same DNA concentrations and even lower DNA concentrations with further subculturing. There might be a possible reduction in copy number with further subculturing, and therefore decreased expression of ESF1 peptide. This could be attributed to an unstable inheritance of the recombinant plasmid vector through each generation resulting from subculturing of the recombinant yeast culture. The possibility of protease degradation of ESF1 peptide is unlikely, because the S. cerevisiae c13ABYS86 strain carries the prb and prc genetic markers which are deficient in the major vacuolar proteases.

The ESF1 gene sequence was designed for optimal expression in E. coli, although analysis of the codons shows a high percentage correlation with yeast codon usage when compared with yeast codon usage tables in literature (Bennetzen and Hall, 1982; http://www.gcg.com/techsupport/data/yeast-high. ) Eckart and Bussineau (1996) commented that codon usage can play a role in regulating gene expression, and in the production of large quantities of high quality heterologous protein. The ESF1 gene sequence contains a high percentage similarity but not an optimal codon usage. This suboptimal codon usage could be a factor that may have contributed to the inefficient production of large quantities of peptide from yeast transformants.

It is also uncertain whether there may have been a rate-limiting cleavage of the LYS-ARG dipeptide by the Kex2 protease which was reported in the expression of drosomycin in the same pTG3828 vector and S. cerevisiae c13ABYS86 strain (Michaut et al., 1996). Mature drosomycin was being produced at a low level (25%), with various N-terminally extended drosomycin peptide products (Michaut et al.,1996). Michaut et al. (1996), also reported from 25% to 90% increase in production of completely
processed drosomycin after coexpressing the Kex2 endoprotease with drosomycin, by inserting a full length \textit{KEX2} gene next to the \textit{drosomycin} gene sequence. Another example of a Kex2 protease processing problem and its effects on concomitant secretion is described in the production of insulin precursor, wherein efficiency of expression was improved by inserting a removable spacer peptide between the \(\alpha\)-factor-leader and the insulin precursor genes (Kjeldsen \textit{et al.}, 1996). Amino acid analysis of the PVDF blotted band (figure 17), thought to be ESF1 revealed amino acids also present in the MF\(\alpha\)1 prosequence, and this may suggest incomplete processing of the ESF1 peptide, and resultant low production and yield of ESF1 peptide after HPLC purification.
CHAPTER FOUR
CONCLUSION
This study has shown that it is possible to produce and secrete biologically active ESF1 peptide in yeast. The yeast expression system has correctly processed the ESF1 peptide such that it retains its biological activity. Although, the yeast expression system may not be ideal for the mass production of heterologous peptides, it can be used to determine whether synthetically designed antimicrobial peptides will retain their activity when produced in a eukaryotic biological system. This has significance when synthetic peptides with enhanced activity are designed with the lack of knowledge of how they would react in a biological system. The numerous synthetic peptides that are presently being designed leads also to the design of an equally large number of antimicrobial peptide gene sequences; and if these peptides are stably produced with intact biological activity in a biological system, they may provide the organism e.g., crop plant in which they are produced with intrinsic resistance to the appropriate microbial pathogen that they are active against.

In our experience, we were able to get better yields from freshly transformed cultures. Unstable inheritance of the recombinant plasmid could be a contributing factor to an increasingly lower copy number after subculturing of the recombinant yeast culture, and this may decrease the production levels. A precise determination of copy number would have to be done to corroborate this. There was, however, a distinct correlation between the yields of plasmid obtained and the number of passages the culture had been through. Whether this relates to copy number or some other phenomenon, needs to be determined to gain a better understanding for the optimization of production.

Production of secreted antimicrobial peptides by recombinant yeast systems may still require optimization through increasing peptide expression levels. This could be achieved by improving the strength and regulation of the promoters used to drive expression, exploring more efficient yeast transformation methods, overexpressing signal peptide proteases to ensure proper processing of mature foreign proteins, and optimizing codon usage.
CHAPTER FIVE

REFERENCES


Falla, T.J., Karunaratne, D.N., and Hancock, R.E.W. 1996. Mode of action of


